Subject Index

AB C DEF GHI JKL MNO PQRS TUV WXYZ

Click on a letter to get an alphabetic listing of Subjects.

Chapters in boldface indicate a major discussion of a topic.

Please also note that due to the impressive size of this index it was necessary to break it down in to smaller groups. The Alphabet above will take you to any letter you please and the grouping of letters is indicated by spaces between the letters.

Main Menu 
Search 
Contributor Index 

Subject Index G
GABA. See Gamma-aminobutyric acid
GAG. See Glycosaminoglycans
Gait assessment, in dizzy patient, (Clinical Volume 2, Chapter 18) 
Galactocerebroside-beta-galactosidase deficiency, in Krabbe disease, (Clinical Volume 3, Chapter 29) (Clinical Volume 5, Chapter 19) 
-Galactosidase A deficiency (Fabry disease), (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 54B) 
Galactosyl-ceramidase deficiency, in Krabbe disease, (Clinical Volume 5, Chapter 19) 
Galactosylceramide lipidosis (Krabbe disease), (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 54B) 
Galardin, in chemical injuries, (Clinical Volume 4, Chapter 28) 
Galilean telescope, (Clinical Volume 1, Chapter 30) 
Gamma-aminobutyric acid (GABA)
in horizontal cells, (Foundations Volume 1, Chapter 19) 
in retinal information processing, (Foundations Volume 1, Chapter 20) 
Gamma globulin. See Immunoglobulin G
Gammopathy, monoclonal, in necrobiotic xanthogranuloma, (Clinical Volume 2, Chapter 35) 
Ganciclovir
alternative strategies, (Foundations Volume 3, Chapter 37) 
in cytomegalovirus infection, retinitis, (Clinical Volume 3, Chapter 28A) 
effects on survival, (Foundations Volume 3, Chapter 37) 
implant, (Foundations Volume 3, Chapter 37) 
in cytomegalovirus retinitis, (Clinical Volume 3, Chapter 28A) 
intravitreal, in cytomegalovirus retinitis, (Clinical Volume 3, Chapter 28A) 
maintenance therapy, (Foundations Volume 3, Chapter 37) 
penetration and pharmacokinetics, (Foundations Volume 2, Chapter 100) 
for progressive outer retinal necrosis syndrome, (Clinical Volume 3, Chapter 28) 
prophylactic, cytomegalovirus and, (Foundations Volume 2, Chapter 64) 
Ganglion cells, on/off dichotomy, (Clinical Volume 2, Chapter 10) 
Ganglion cells, retinal, (Clinical Volume 1, Chapter 33) (Clinical Volume 2, Chapter 4) (Clinical Volume 3, Chapter 1) 
axon-derived survival factors, replacement, (Clinical Volume 3, Chapter 57) 
in Niemann-Pick disease, (Clinical Volume 3, Chapter 29) 
parallel visual pathways, (Clinical Volume 2, Chapter 2) 
photoreceptor function of, (Foundations Volume 1, Chapter 19) 
in primary open-angle glaucoma, (Clinical Volume 3, Chapter 52) 
proapoptotic and antiapoptotic signaling
neuroprotection aimed at, (Clinical Volume 3, Chapter 57) 
regeneration
neuroprotection aimed at, (Clinical Volume 3, Chapter 57) 
survival, after optic nerve damage or ischemia, (Clinical Volume 3, Chapter 57) 
Gangliosidoses, (Clinical Volume 5, Chapter 19)  (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 54B) 
Gangliosidosis, generalized, (Clinical Volume 5, Chapter 30) 
Gangrene, eyelid, (Clinical Volume 5, Chapter 75) 
Garamycin. See Gentamicin (Garamycin)
Gas bubbles, glaucoma and, (Clinical Volume 3, Chapter 54E) 
Gas(es)
intraocular
absorption and kinetics, (Clinical Volume 6, Chapter 54) 
as vitreous substitutes, (Clinical Volume 6, Chapter 54) 
therapeutic, ocular toxicity, (Clinical Volume 5, Chapter 37) 
Gas-liquid chromatography, (Foundations Volume 2, Chapter 40) 
Gas-permeable lenses
complications, (Clinical Volume 4, Chapter 27) See also Contact lenses, complications
giant papillary conjunctivitis and, (Clinical Volume 4, Chapter 9A) 
Gass, peculiar foveomacular dystrophy of, (Clinical Volume 3, Chapter 9) 
Gastrointestinal agents, ocular toxicity, (Clinical Volume 5, Chapter 37) 
Gastrointestinal diseases, ocular manifestations, (Clinical Volume 5, Chapter 30) 
central corneal opacification, hepatomegaly, (Clinical Volume 5, Chapter 30) 
conjunctival manifestations, (Clinical Volume 5, Chapter 30) 
keratoconjunctivitis sicca, (Clinical Volume 5, Chapter 30) 
lysosomal storage diseases, (Clinical Volume 5, Chapter 30) 
corneal manifestations, (Clinical Volume 5, Chapter 30) 
Alagille syndrome, peripheral corneal changes in, (Clinical Volume 5, Chapter 30) 
peripheral corneal rings, non-Wilsonian chronic liver disease, (Clinical Volume 5, Chapter 30) 
Wilson’s disease, cornea in, (Clinical Volume 5, Chapter 30) 
eyelid manifestations, (Clinical Volume 5, Chapter 30) 
inflammatory bowel disease, (Clinical Volume 5, Chapter 30) 
Crohn’s disease, (Clinical Volume 5, Chapter 30) 
genetic susceptibility to, (Clinical Volume 5, Chapter 30) 
ulcerative colitis, (Clinical Volume 5, Chapter 30) 
lens manifestations, (Clinical Volume 5, Chapter 30) 
cerebrotendinous xanthomatosis, (Clinical Volume 5, Chapter 30) 
Zellweger syndrome, (Clinical Volume 5, Chapter 30) 
neuro-ophthalmologic manifestations, (Clinical Volume 5, Chapter 30) 
gaze palsies, oculomotor apraxia, (Clinical Volume 5, Chapter 30) 
optic nerve, visual pathway disorders, (Clinical Volume 5, Chapter 30) 
viral hepatitis, corneal transplantation, (Clinical Volume 5, Chapter 30) 
Wernicke’s encephalopathy, (Clinical Volume 5, Chapter 30) 
orbital manifestations, (Clinical Volume 5, Chapter 30) 
pancreatitis, retinopathy in, (Clinical Volume 5, Chapter 30) 
retinal manifestations, (Clinical Volume 5, Chapter 30) 
abetalipoproteinemia, pigmentary retinopathy in, (Clinical Volume 5, Chapter 30) 
Gaucher’s disease, (Clinical Volume 5, Chapter 30) 
generalized gangliosidosis, (Clinical Volume 5, Chapter 30) 
glycogen storage diseases, perimacular retinal deposits in, (Clinical Volume 5, Chapter 30) 
peroxisomal disorders, pigmentary retinopathy in, (Clinical Volume 5, Chapter 30) 
pigmentary retinopathy in systemic mucopolysaccaridoses, (Clinical Volume 5, Chapter 30) 
sphingolipidoses, perimacular retinal deposits in, (Clinical Volume 5, Chapter 30) 
retinal pigment epithelium, congenital hypertrophy of, in familial adenomatous polyposis coli, (Clinical Volume 5, Chapter 30) 
retinal vitamin A deficiency, hepatobiliary, (Clinical Volume 5, Chapter 30) 
uveal manifestations, (Clinical Volume 5, Chapter 30) 
Whipple’s disease, (Clinical Volume 5, Chapter 30) 
Gastrointestinal disorders, (Clinical Volume 5, Chapter 30 ) 
angle-closure glaucoma mimicking, (Clinical Volume 3, Chapter 53) 
bleeding, and ischemic optic neuropathy, (Clinical Volume 2, Chapter 5) 
cephalosporins and, (Clinical Volume 4, Chapter 18) 
conjunctival manifestations, (Clinical Volume 5, Chapter 30) 
in Dego’s syndrome, (Clinical Volume 5, Chapter 27) 
lens manifestations, (Clinical Volume 5, Chapter 30) 
lid manifestations, (Clinical Volume 5, Chapter 30) 
neuro-ophthalmologic manifestations, (Clinical Volume 5, Chapter 30) 
orbital manifestations, (Clinical Volume 5, Chapter 30) 
postoperative, in children, (Clinical Volume 6, Chapter 81) 
retinal manifestations, (Clinical Volume 5, Chapter 30) 
scleral manifestations, (Clinical Volume 5, Chapter 30) 
vascular manifestations, (Clinical Volume 5, Chapter 30) 
Gastrointestinal toxicity, NSAIDs and, (Foundations Volume 3, Chapter 38) 
Gaussian reduction, thick lens
Gaze
common disturbances of, with hemispheric lesions, (Foundations Volume 1, Chapter 38) 
direction, during retrobulbar anesthesia, (Clinical Volume 6, Chapter 1) 
downward
limited, saccadic velocity in, (Clinical Volume 1, Chapter 21) 
in progressive supranuclear palsy, (Clinical Volume 2, Chapter 12) 
in thyroid orbitopathy, (Clinical Volume 2, Chapter 36) 
functional disturbances, (Clinical Volume 2, Chapter 10) 
functional disturbances of, (Clinical Volume 2, Chapter 10) 
palsies
in gastrointestinal disorders, (Clinical Volume 5, Chapter 30) 
palsy, in myasthenia gravis, (Clinical Volume 1, Chapter 20) 
psychic paralysis, (Clinical Volume 2, Chapter 7) 
torsional, lesions affecting, (Clinical Volume 2, Chapter 10) 
unilateral hemispheric lesions affecting, (Clinical Volume 2, Chapter 10) 
vertical, (Clinical Volume 1, Chapter 4) . See also Dissociated vertical deviations
in dorsal midbrain syndrome, (Clinical Volume 2, Chapter 12) 
lesions affecting, (Clinical Volume 2, Chapter 10) 
vertical and torsional, (Foundations Volume 1, Chapter 38 ) 
Gaze function
disturbances in, hemispheric lesions and, (Foundations Volume 1, Chapter 38) 
Gelatinous droplike dystrophy, (Clinical Volume 4, Chapter 16) 
Gender. See Sex
Gene amplification, (Foundations Volume 2, Chapter 40) 
Gene dose, chromosomal abnormalities and, (Foundations Volume 3, Chapter 52) 
General anesthetics, ocular toxicity, (Clinical Volume 5, Chapter 37) 
Generalized cataract, (Foundations Volume 1, Chapter 15) 
Generalized chorioretinal dystrophies. See specific type
Generalized gangliosidosis, (Foundations Volume 3, Chapter 54B) 
Gene(s)
candidate, (Foundations Volume 3, Chapter 55) 
screening, human genome sequence and, (Foundations Volume 1, Chapter 19A) 
disorders, associated with strabismus, (Foundations Volume 3, Chapter 59) 
Epstein-Barr virus, expression
during latent stages of infection, (Foundations Volume 2, Chapter 91) 
during lytic stages of infection, (Foundations Volume 2, Chapter 91) 
eye-specific, database, (Foundations Volume 1, Chapter 19A) 
mutation. (See Mutation)
structure and function, (Foundations Volume 3, Chapter 55) 
uveitis immunogenetics, (Foundations Volume 2, Chapter 28A) 
Genes, associated with glaucoma, nomenclature for, (Clinical Volume 3, Chapter 50) 
Genetic counseling/preconception counseling, (Foundations Volume 3, Chapter 56) 
Genetic heterogeneity, (Foundations Volume 3, Chapter 55) 
Genetics. See also Chromosomal abnormalities; Chromosome; Cytogenetics; Hereditary factors; Inheritance; Molecular genetics
of ankylosing spondylitis, (Foundations Volume 2, Chapter 33) 
of color vision defects, (Foundations Volume 3, Chapter 55) 
of congenital stationary night blindness, (Foundations Volume 3, Chapter 55) 
of familial exudative vitreoretinopathy, (Foundations Volume 3, Chapter 55) 
of Leber’s hereditary optic neuropathy, (Foundations Volume 3, Chapter 55) 
of macular degeneration, (Foundations Volume 3, Chapter 55) 
of Marfan’s syndrome, (Foundations Volume 3, Chapter 55) 
of melanoma, uveal, (Foundations Volume 3, Chapter 55) 
of neurofibromatosis, (Foundations Volume 3, Chapter 55) 
of Norrie’s disease, (Foundations Volume 3, Chapter 55) 
of retinal degeneration, (Foundations Volume 2, Chapter 12) 
of retinitis pigmentosa, (Foundations Volume 3, Chapter 55) 
of tuberous sclerosis, (Foundations Volume 3, Chapter 55) 
of von Hippel-Lindau disease, (Foundations Volume 3, Chapter 55) 
of Wilson’s disease, (Foundations Volume 3, Chapter 54B) 
Genetic transference, ocular infections and, (Foundations Volume 2, Chapter 65) 
Genetic transmission of resistance of ocular infections, (Foundations Volume 2, Chapter 65) 
Geniculate body, lateral. See Lateral geniculate nucleus
Geniculocalcarine blindness, transient. See Blindness, transient
Geniculocalcarine fibers tract, (Foundations Volume 1, Chapter 34) 
Geniculocalcarine radiations, (Clinical Volume 2, Chapter 4) 
distribution of fibers, (Clinical Volume 2, Chapter 4) 
Genome
human herpesvirus 6, (Foundations Volume 2, Chapter 93) 
human herpesvirus 7, (Foundations Volume 2, Chapter 93) 
human herpesvirus 8, (Foundations Volume 2, Chapter 93A) 
mitochondrial, maternal inheritance of, (Foundations Volume 1, Chapter 19A) 
Genomic analysis
retinal pigment epithelium, (Foundations Volume 1, Chapter 21) 
Gentamicin (Garamycin), (Clinical Volume 4, Chapter 26) (Foundations Volume 3, Chapter 39) 
in cat-scratch disease, (Clinical Volume 4, Chapter 4) 
in ecthyma gangrenosum, (Clinical Volume 4, Chapter 22) 
fortified topical preparation, (Clinical Volume 4, Chapter 18) 
intravitreal injection, (Clinical Volume 4, Chapter 26) 
in ophthalmia neonatorum, (Clinical Volume 4, Chapter 6) 
preparation for intraocular administration, (Clinical Volume 4, Chapter 24) 
prophylactic use
tissue transplantation and, (Foundations Volume 2, Chapter 64) 
side effects, in infants and children, (Foundations Volume 3, Chapter 43) 
systemic toxicity, (Clinical Volume 5, Chapter 37) 
Geographic and preventive ophthalmology, (Clinical Volume 5, Chapter 50) 
Hansen’s disease, (Clinical Volume 5, Chapter 63 ) 
nutritional blindness, (Clinical Volume 5, Chapter 59 ) 
screening, (Clinical Volume 5, Chapter 54) See also Screening
sports-related eye injuries and, (Clinical Volume 5, Chapter 45) See also Sports medicine
Third World ophthalmology, (Clinical Volume 5, Chapter 58 ) 
Geographic helicoid peripapillary choroidopathy. See Choroiditis, serpiginous
Geographic ophthalmology, (Foundations Volume 2, Chapter 43) 
Geometric horopter, (Foundations Volume 2, Chapter 24) See also Horopter
Geometric optics, (Clinical Volume 1, Chapter 30) See also Optics; Physical optics
aberrations, (Clinical Volume 1, Chapter 30) See also Aberrations of eye
axial magnification, (Clinical Volume 1, Chapter 30) 
clinical examples, (Clinical Volume 1, Chapter 30) 
cylindrical lenses, (Clinical Volume 1, Chapter 30) 
diffraction, (Clinical Volume 1, Chapter 30) See also Diffraction
Fermat’s principle, (Clinical Volume 1, Chapter 30) 
image location
infinite conjugates, (Clinical Volume 1, Chapter 30) 
lens shape and fabrication, (Clinical Volume 1, Chapter 30) 
nonstigmatic image, (Clinical Volume 1, Chapter 30) 
reflection, (Clinical Volume 1, Chapter 30) See also Reflection
refraction, (Clinical Volume 1, Chapter 30) See also Refraction
refractive index, (Clinical Volume 1, Chapter 30) 
thin lens approximation, (Clinical Volume 1, Chapter 30) 
vergence, (Clinical Volume 1, Chapter 30) See also Vergence
virtual images and objects, (Clinical Volume 1, Chapter 30) 
Geriatric conditions. See Age
German measles. See Rubella
Geshwind syndrome, (Clinical Volume 2, Chapter 4) 
GFAP. See Glial fibrillary acidic protein
Ghost cells, vitreous hemorrhage and, (Foundations Volume 3, Chapter 6) 
Ghost erythrocytes, (Clinical Volume 3, Chapter 7) 
“Giant drusen, ”, (2) 5: 21
Gibbs-Donnan equilibrium, (Foundations Volume 2, Chapter 6) 
Gilchrist disease. See Blastomycosis
Gillespie syndrome, (Foundations Volume 1, Chapter 40) 
Girdle fibers, circumferential, zonular, (Foundations Volume 1, Chapter 14) 
Glare, (Clinical Volume 1, Chapter 31) 
laser iridectomy and, (Clinical Volume 6, Chapter 19) 
tissue light scattering and, contrast sensitivity and, (Clinical Volume 1, Chapter 35) 
Glare sensitivity, (Clinical Volume 1, Chapter 35 ) 
clinical conditions affecting, (Clinical Volume 1, Chapter 35) 
occupational ophthalmology and, (Clinical Volume 5, Chapter 47) 
opacified posterior capsules and, (Clinical Volume 1, Chapter 35) 
surgical correction of disability, (Clinical Volume 1, Chapter 31) 
Glassblowers’ cataract, (Clinical Volume 1, Chapter 73) 
Glasses, corrective. See Spectacle lenses
Glaucoma, (Foundations Volume 3, Chapter 19)  (Clinical Volume 3, Chapter 31) (Clinical Volume 3, Chapter 55) (Clinical Volume 6, Chapter 59) 
after penetrating keratoplasty, (Clinical Volume 3, Chapter 54F) 
angle-closure, (Clinical Volume 3, Chapter 41) (Clinical Volume 3, Chapter 53 ) 
accommodation in, (Clinical Volume 3, Chapter 53) 
anatomic factors, (Clinical Volume 3, Chapter 53) 
anterior chamber angle depth in, (Clinical Volume 3, Chapter 53) 
anterior chamber angle width and, (Clinical Volume 3, Chapter 53) 
in aphakia and pseudophakia, (Clinical Volume 3, Chapter 54G ) 
argon laser gonioplasty, (Clinical Volume 6, Chapter 19) 
carotid artery disease and, (Clinical Volume 3, Chapter 54E) 
central retinal artery occlusion and, (Clinical Volume 3, Chapter 54E) 
central retinal vein occlusion and, (Clinical Volume 3, Chapter 54E) 
choroidal tumors and, (Clinical Volume 3, Chapter 54E) 
dilation of pupil, (Clinical Volume 3, Chapter 53) 
exfoliation syndrome and, (Clinical Volume 3, Chapter 54B) 
human immunodeficiency virus and, (Clinical Volume 3, Chapter 54E) 
iridotomy, laser, (Clinical Volume 3, Chapter 53) 
iris in, anatomic configuration, (Clinical Volume 3, Chapter 53) 
iris retraction syndrome of Campbell, (Clinical Volume 3, Chapter 54E) 
medical therapy, (Clinical Volume 3, Chapter 53) 
tension response to, (Clinical Volume 3, Chapter 53) 
metastatic tumors and, (Clinical Volume 3, Chapter 54E) 
microspherophakia and, (Clinical Volume 3, Chapter 51) 
multiple ocular diseases and, (Clinical Volume 3, Chapter 53) 
with open-angle glaucoma, (Clinical Volume 3, Chapter 53) 
pathophysiologic factors, (Clinical Volume 3, Chapter 53) 
persistent fetal vasculature and, (Clinical Volume 3, Chapter 54E) 
photocoagulation and, (Clinical Volume 6, Chapter 76) 
physiologic factors, (Clinical Volume 3, Chapter 53) 
plateau iris and, (Clinical Volume 3, Chapter 53) 
posterior chamber, argon laser gonioplasty, (Clinical Volume 6, Chapter 19) 
postoperative panretinal photocoagulation and, (Clinical Volume 3, Chapter 54E) 
postoperative scleral buckling and, (Clinical Volume 3, Chapter 54E) 
prediction of potential cases, (Clinical Volume 3, Chapter 53) 
primary, (Clinical Volume 3, Chapter 53 ) 
due to pupillary block, cataracts and, (Clinical Volume 3, Chapter 55) 
without pupillary block, (Clinical Volume 3, Chapter 53) 
provocative tests, (Clinical Volume 3, Chapter 53) 
relative pupillary block in, (Clinical Volume 3, Chapter 53) 
retinal disorders and, (Clinical Volume 3, Chapter 54E ) 
retinal dysplasia and, (Clinical Volume 3, Chapter 54E) 
retinopathy of prematurity and, (Clinical Volume 3, Chapter 54E) 
angle closure. (See Glaucoma, closed angle)
in anterior segment anomalies, (Clinical Volume 3, Chapter 55) 
anterior uveitis and, (Clinical Volume 3, Chapter 54D) 
aphakic, after cataract surgery, (Foundations Volume 3, Chapter 6) 
associated with other genetic disorders, (Clinical Volume 3, Chapter 50) 
automated perimetry in, (Foundations Volume 2, Chapter 109) 
in Axenfeld’s anomaly and syndrome, (Clinical Volume 3, Chapter 51) (Clinical Volume 3, Chapter 55) 
Beta-adrenergic blocking agents in, (Clinical Volume 3, Chapter 56) 
aqueous humor dynamics and, (Clinical Volume 3, Chapter 56) 
baseline pressure and, (Clinical Volume 3, Chapter 56) 
carbonic anhydrase inhibitors, (Clinical Volume 3, Chapter 56) 
clinical perspectives, (Clinical Volume 3, Chapter 56) 
demecarium bromide, (Clinical Volume 3, Chapter 56) 
diispropylfluorophosphate, (Clinical Volume 3, Chapter 56) 
drug delivery in, (Clinical Volume 3, Chapter 56) 
hyperosmotic agents, (Clinical Volume 3, Chapter 56) 
one-eyed therapeutic trials, (Clinical Volume 3, Chapter 56) 
parasympathomimetic agents, (Clinical Volume 3, Chapter 56) See also Parasympathomimetic agents
receptor physiology and, (Clinical Volume 3, Chapter 56) 
blindness and, 5–7, (Clinical Volume 5, Chapter 53) 
capsular, HLA antigen association, (Foundations Volume 2, Chapter 38) 
carbonic anhydrase inhibitors in, (Foundations Volume 3, Chapter 30 ) 
carotid artery disease and, (Clinical Volume 3, Chapter 54E) 
carotid-cavernous fistula and, (Clinical Volume 3, Chapter 54E) 
chorioretinal atrophy in, (Clinical Volume 4, Chapter 66) 
chronic simple. (See Glaucoma, open-angle)
ciliary block, (Foundations Volume 3, Chapter 19) 
muscarinic antagonists and, (Foundations Volume 3, Chapter 26) 
closed angle, (Foundations Volume 3, Chapter 19) 
after retinal reattachment, (Foundations Volume 3, Chapter 6) 
muscarinic agonists and
muscarinic antagonists and, (Foundations Volume 3, Chapter 26) 
posterior synechiae-induced, (Foundations Volume 3, Chapter 19) 
ultrasound biomicroscopy, (Foundations Volume 2, Chapter 106) 
color Doppler imaging, (Foundations Volume 2, Chapter 102) 
combined mechanism, (Clinical Volume 3, Chapter 53) 
confocal scanning laser ophthalmoscopy, (Foundations Volume 2, Chapter 111) 
corneal disorders and, (Clinical Volume 3, Chapter 54F ) 
developmental, (Clinical Volume 3, Chapter 51 ) 
anatomic classification of, (Clinical Volume 3, Chapter 51) 
associated disorders, (Clinical Volume 3, Chapter 51) 
Axenfeld’s anomaly and syndrome and, (Clinical Volume 3, Chapter 51) 
birth trauma and, (Clinical Volume 3, Chapter 51) 
chromosome abnormalities and, (Clinical Volume 3, Chapter 51) 
clinical presentation, (Clinical Volume 3, Chapter 51) 
congenital anomalies associated with, (Clinical Volume 3, Chapter 51) 
corneotrabeculodysgenesis and, (Clinical Volume 3, Chapter 51) 
familial iris hypoplasia and, (Clinical Volume 3, Chapter 51) 
in homocystinuria, (Clinical Volume 3, Chapter 51) 
Hoskin’s classification, (Clinical Volume 3, Chapter 51) 
inflammation and, (Clinical Volume 3, Chapter 51) 
iridodysgenesis and, (Clinical Volume 3, Chapter 51) 
in Marfan syndrome, (Clinical Volume 3, Chapter 51) 
in microspherophakia, (Clinical Volume 3, Chapter 51) 
in neurofibromatosis, (Clinical Volume 3, Chapter 51) 
persistent hyperplastic primary vitreous and, (Clinical Volume 3, Chapter 51) 
Peters’ anomaly and, (Clinical Volume 3, Chapter 51) 
in Pierre Robin syndrome, (Clinical Volume 3, Chapter 51) 
Rieger’s anomaly and syndrome and, (Clinical Volume 3, Chapter 51) 
in Rubinstein-Taybi syndrome, (Clinical Volume 3, Chapter 51) 
Sturge-Weber syndrome and, (Clinical Volume 3, Chapter 51) 
trabeculodysgenesis and, 3, (Clinical Volume 3, Chapter 51) 
drainage implant devices in, (Clinical Volume 3, Chapter 52) 
early, field defects, (Clinical Volume 3, Chapter 49) 
in Edward’s syndrome, (Clinical Volume 3, Chapter 55) 
electrophysiologic testing in, (Clinical Volume 3, Chapter 5) 
embryologic development and, (Foundations Volume 3, Chapter 19) 
in embryotoxon, posterior, (Clinical Volume 3, Chapter 51) 
expanding gases and, (Clinical Volume 3, Chapter 54E) 
field defects in, (Clinical Volume 2, Chapter 5) (Clinical Volume 3, Chapter 49) See also Field defects, in glaucoma
filtering surgery, (Clinical Volume 3, Chapter 52) (Clinical Volume 3, Chapter 53) See also Trabe culectomy
in exfoliative glaucoma, (Clinical Volume 3, Chapter 54B) 
overfiltration, hypotony due to, (Clinical Volume 3, Chapter 58) 
in pigmentary glaucoma, (Clinical Volume 3, Chapter 54B) 
in Sturge-Weber syndrome, (Clinical Volume 3, Chapter 51) 
Fuchs’ endothelial dystrophy and, (Clinical Volume 3, Chapter 54F) 
in Fuchs’ syndrome, (Clinical Volume 3, Chapter 55) 
in Hallermann-Streiff syndrome, (Clinical Volume 3, Chapter 55) 
hemodialysis and, (Clinical Volume 5, Chapter 31) 
in herpes simplex infection, (Clinical Volume 3, Chapter 54F) 
in heterochromic iridocyclitis, (Clinical Volume 4, Chapter 42) 
historical aspects, (Clinical Volume 3, Chapter 41 ) 
impaired outflow and, (Foundations Volume 3, Chapter 19 ) 
indirect-acting muscarinic agonists in, (Foundations Volume 3, Chapter 26) 
initiating factors, (Clinical Volume 3, Chapter 57) 
intraocular lens and, (Foundations Volume 3, Chapter 6) 
intraocular pressure in, (Foundations Volume 2, Chapter 7) 
carbonic anhydrase inhibitors in reduction, (Foundations Volume 3, Chapter 30) 
diurnal variation, (Foundations Volume 2, Chapter 7) 
water-provocative test and, (Foundations Volume 2, Chapter 7) 
iridectomy, laser, (Clinical Volume 6, Chapter 19 ) 
iridocorneal endothelial syndrome and, (Clinical Volume 3, Chapter 54F) 
in iridocorneal mesodermal dysgenesis, (Clinical Volume 3, Chapter 55) 
iris retraction syndrome of Campbell and, (Clinical Volume 3, Chapter 54E) 
juvenile, trabecular meshwork in, (Foundations Volume 1, Chapter 10) 
malignant, (Foundations Volume 3, Chapter 19) (Clinical Volume 3, Chapter 53)  (Clinical Volume 3, Chapter 55) 
after cataract surgery, (Clinical Volume 3, Chapter 54G) 
after glaucoma surgery, (Clinical Volume 6, Chapter 24) 
Chandler’s vitreous operation in, (Clinical Volume 3, Chapter 53 ) 
preliminary confirmation procedure for, (Clinical Volume 3, Chapter 53) 
clinical features, (Clinical Volume 3, Chapter 53) 
differential diagnosis, (Clinical Volume 3, Chapter 53) 
medical treatment, (Clinical Volume 3, Chapter 53) 
muscarinic antagonists and, (Foundations Volume 3, Chapter 26) 
mydriatic-cycloplegic therapy, (Clinical Volume 3, Chapter 53) 
Nd:YAG hyaloidotomy, (Clinical Volume 6, Chapter 19) 
surgical treatment, (Clinical Volume 3, Chapter 53) 
treatment protocol, (Clinical Volume 3, Chapter 53) 
mechanism of ocular hypertension and, (Clinical Volume 3, Chapter 41) 
model, chronic elevated intraocular pressure and, (Clinical Volume 3, Chapter 57) 
nail-patella syndrome and, (Clinical Volume 3, Chapter 50) 
nanophthalmos and, (Clinical Volume 3, Chapter 50) 
narrow angle, (Foundations Volume 3, Chapter 19) 
muscarinic antagonists and, (Foundations Volume 3, Chapter 26) 
narrow-angle. (See Glaucoma, angle-closure)
neuroprotection mechanisms, (Clinical Volume 3, Chapter 57) 
apoptosis, BCL-family proteins in, (Clinical Volume 3, Chapter 57) 
axon-derived survival factors, replacing, (Clinical Volume 3, Chapter 57) 
axons, neuroprotection of, (Clinical Volume 3, Chapter 57) 
glial cells, neuroprotection aimed at, (Clinical Volume 3, Chapter 57) 
glutamate excitotoxicity, (Clinical Volume 3, Chapter 57) 
initiating factors, (Clinical Volume 3, Chapter 57) 
intracellular apoptosis signaling, neuroprotection aimed at, (Clinical Volume 3, Chapter 57) 
mediators with destructive, protective actions, (Clinical Volume 3, Chapter 57) 
mitochondria, apoptosis signaling by, (Clinical Volume 3, Chapter 57) 
preconditioning, endogenous neuroprotection mediated by, (Clinical Volume 3, Chapter 57) 
retinal ganglion cell death, protein mediators of, (Clinical Volume 3, Chapter 57) 
retinal ganglion cells, neuroprotection of, (Clinical Volume 3, Chapter 57) 
secondary retinal ganglion cell death, mediators of, (Clinical Volume 3, Chapter 57) 
neuroprotection mechanisms in, (Clinical Volume 3, Chapter 57 ) 
neuroprotective therapies in, (Clinical Volume 3, Chapter 57) 
normal outflow and, (Foundations Volume 3, Chapter 19) 
normotensive. (See Glaucoma, low tension)
open-angle, (Clinical Volume 3, Chapter 41) (Clinical Volume 3, Chapter 53) (Clinical Volume 6, Chapter 15) (Clinical Volume 3, Chapter 55) 
with angle-closure glaucoma, (Clinical Volume 3, Chapter 53) 
carotid-cavernous fistula and, (Clinical Volume 3, Chapter 54E) 
chronic
Doppler effect and, (Clinical Volume 1, Chapter 31) 
vitrectomy causing, (Clinical Volume 6, Chapter 56) 
complex inheritance of, (Clinical Volume 3, Chapter 50) 
cyclodestructive procedures, (Clinical Volume 3, Chapter 52) 
diabetes mellitus and, (Clinical Volume 5, Chapter 20) 
differential diagnosis, (Clinical Volume 3, Chapter 52) 
due to Beta-chymotrypsin, cataract and, (Clinical Volume 3, Chapter 55) 
episcleral venous pressure and, (Clinical Volume 3, Chapter 54E) 
in exfoliation syndrome, (Clinical Volume 3, Chapter 55) 
foreign body siderosis and, (Clinical Volume 3, Chapter 54E) 
in Fuchs’ endothelial dystrophy, (Clinical Volume 3, Chapter 55) 
in Fuchs’ heterochromic iridocyclitis, (Clinical Volume 3, Chapter 55) 
genetics, (Clinical Volume 3, Chapter 50) 
evidence from epidemiology, (Clinical Volume 3, Chapter 50) 
genetic screening for, (Clinical Volume 3, Chapter 50) 
in interstitial keratitis, (Clinical Volume 3, Chapter 55) 
intraocular pressure in, (Clinical Volume 3, Chapter 52) 
in iridocyclitis, (Clinical Volume 3, Chapter 55) 
laser trabeculoplasty, (Clinical Volume 3, Chapter 52) 
in Marfan syndrome, (Clinical Volume 3, Chapter 51) 
muscarinic agonists and, (Foundations Volume 3, Chapter 26) 
muscarinic antagonists and, (Foundations Volume 3, Chapter 26) 
optic nerve head in, (Clinical Volume 3, Chapter 52) 
outflow pathways in, (Clinical Volume 3, Chapter 52) 
pseudophakia and, (Clinical Volume 3, Chapter 55) 
red blood cell-related, (Clinical Volume 3, Chapter 54E) 
retinal disorders and, (Clinical Volume 3, Chapter 54E ) 
retinal ganglion cells in, (Clinical Volume 3, Chapter 52) 
retinal nerve fiber layer in, (Clinical Volume 3, Chapter 52) 
in retinal vein occlusion, central, (Clinical Volume 3, Chapter 15) 
retinitis pigmentosa and, 3, (Clinical Volume 3, Chapter 54E) 
Schwartz syndrome and, (Clinical Volume 3, Chapter 54E) 
silicone oil/gas and, (Clinical Volume 3, Chapter 54E) 
steroid responsiveness and, (Foundations Volume 2, Chapter 7) 
Stickler’s syndrome and, (Clinical Volume 3, Chapter 54E) 
Sturge-Weber syndrome and, (Clinical Volume 3, Chapter 54E) 
superior vena cava syndrome and, (Clinical Volume 3, Chapter 54E) 
surgery, (Clinical Volume 3, Chapter 52) 
considerations in cataract patients, (Clinical Volume 3, Chapter 55) 
effects on intraocular pressure, (Clinical Volume 3, Chapter 52) 
guarded filtration procedures, (Clinical Volume 6, Chapter 15 ) 
ultrasound biomicroscopy, (Foundations Volume 2, Chapter 106) 
optical coherence tomography, (Foundations Volume 2, Chapter 107) 
in pars planitis, (Clinical Volume 4, Chapter 43) 
in Patau’s syndrome, (Clinical Volume 3, Chapter 55) 
photocoagulation-related, (Clinical Volume 6, Chapter 76) 
plasma osmolality in, (Foundations Volume 2, Chapter 7) 
posterior polymorphous dystrophy and, (Clinical Volume 3, Chapter 54F) 
prediction of, corticosteroid response and, (Foundations Volume 3, Chapter 31) 
primary, (Foundations Volume 3, Chapter 19) 
associated with ocular abnormalities, (Clinical Volume 3, Chapter 50) 
associated with systemic disorders, (Clinical Volume 3, Chapter 50) 
primary angle-closure, (Clinical Volume 6, Chapter 15) 
pseudoexfoliation, (Foundations Volume 3, Chapter 19) 
trabecular meshwork in, (Foundations Volume 1, Chapter 10) 
pseudoexfoliative, (Clinical Volume 3, Chapter 54B) 
pseudophakic, after cataract surgery, (Foundations Volume 3, Chapter 6) 
public health impact, (Clinical Volume 5, Chapter 54) 
pupillary light reflex in, (Foundations Volume 2, Chapter 9) 
red blood cell-related, (Clinical Volume 3, Chapter 54E) 
refractory, tube shunts for, (Clinical Volume 6, Chapter 17) See also Tube shunts
retained lens fragments and, (Clinical Volume 6, Chapter 65) 
retinal disorders and, (Clinical Volume 3, Chapter 54E ) 
retinal dysplasia and, (Clinical Volume 3, Chapter 54E) 
risk factors for, (Clinical Volume 3, Chapter 57) 
in Rubinstein-Taybi syndrome, (Clinical Volume 3, Chapter 51) 
in Schwartz-Matsuo syndrome, (Foundations Volume 3, Chapter 19) 
silicone oil and, (Clinical Volume 6, Chapter 56) 
surgery, (Clinical Volume 6, Chapter 15) See also under specific type of glaucoma
antimetabolites in, (Clinical Volume 6, Chapter 15) 
bandage lenses and, (Clinical Volume 1, Chapter 56) 
cataract extraction and, (Clinical Volume 6, Chapter 16 ) 
conjunctival healing in, (Foundations Volume 1, Chapter 29) 
corticosteroids and, (Foundations Volume 3, Chapter 31) 
cyclocryotherapy, (Clinical Volume 6, Chapter 15) 
cyclodestructive procedures, (Clinical Volume 6, Chapter 15) 
cyclophotocoagulation, (Clinical Volume 6, Chapter 15) 
deep sclerectomy with collagen implant, (Clinical Volume 6, Chapter 15) 
deep sclerectomy with viscocanalostomy, (Clinical Volume 6, Chapter 15) 
evaluation of person in, (Clinical Volume 6, Chapter 15) 
failed, laser treatment, (Clinical Volume 1, Chapter 69B) 
5-fluorouracil in, (Clinical Volume 6, Chapter 15) 
guarded filtration procedures, (Clinical Volume 6, Chapter 15) 
nonpenetrating filtration surgery, (Clinical Volume 6, Chapter 15) 
postoperative care and complications of, (Clinical Volume 6, Chapter 15) 
preoperative care, (Clinical Volume 6, Chapter 15) 
risks and benefits in, (Clinical Volume 6, Chapter 15) 
topical corticosteroids in, (Clinical Volume 6, Chapter 15) 
tube shunts for glaucoma, (Clinical Volume 6, Chapter 15) 
ultrasound biomicroscopy after, (Foundations Volume 2, Chapter 106) 
use of agents that alter inflammation and wound healing in, (Clinical Volume 6, Chapter 15) 
use of slip knots and releasable sutures in, (Clinical Volume 6, Chapter 15) 
in syndrome of inflammatory precipitates on trabecular meshwork, (Clinical Volume 3, Chapter 54D) 
tissue changes caused by elevated pressure in, (Foundations Volume 3, Chapter 19) 
tonography in, (Clinical Volume 2, Chapter 5) See also Tonography
tonometry in, (Clinical Volume 3, Chapter 41) See also Tonometry
trabecular meshwork in, (Foundations Volume 1, Chapter 10 ) 
trabeculoplasty in. (See Trabeculoplasty)
transscleral cyclodestruction in, (Clinical Volume 6, Chapter 19) 
treatment, (Clinical Volume 3, Chapter 51) See also Glaucoma, medical treatment; Glaucoma, surgery
in Sturge-Weber syndrome, (Clinical Volume 5, Chapter 36) 
ultrasound biomicroscopy, (Foundations Volume 2, Chapter 106) 
variable outflow and, (Foundations Volume 3, Chapter 19) 
visual evoked potential in, (Foundations Volume 2, Chapter 105) 
visual field testing in, (Foundations Volume 2, Chapter 17) 
water-provocative test in, (Foundations Volume 2, Chapter 7) 
Glaucoma medical therapy, (Clinical Volume 3, Chapter 55) 
Glaucoma surgery, anesthesia, (Clinical Volume 6, Chapter 1) 
Glial cells
characteristics of, (Foundations Volume 1, Chapter 19) 
retinal, (Foundations Volume 2, Chapter 5) See also Astrocytes; Muller cells
structure and function, (Foundations Volume 1, Chapter 20) 
transformation of stalk cells into, (Foundations Volume 1, Chapter 2) 
Glial fibrillary acidic protein (GFAP), in optic nerve head, (Foundations Volume 1, Chapter 25) 
Glioblastoma multiforme
chiasmal invasion, (Clinical Volume 2, Chapter 6) 
intracranial, orbital extension, (Clinical Volume 2, Chapter 46) 
Glioma, optic nerve, (Foundations Volume 3, Chapter 16) 
Glioneuroma, (1)21: 17
Gliosis
premacular. (See Epiretinal membranes)
Global indices, in field defect identification, (Clinical Volume 3, Chapter 49) 
Global visual field indices, (Clinical Volume 2, Chapter 10) 
Globe. See Eyeball
computed tomography of, (Clinical Volume 2, Chapter 24) 
displacement, (Clinical Volume 2, Chapter 22) 
lacrimal gland tumors and, (Clinical Volume 2, Chapter 40) 
foreign bodies in, (Clinical Volume 2, Chapter 24) 
handling, after enucleation, 5, (Clinical Volume 6, Chapter 109) 
injuries to, sports-related
intraoperative compression of, ischemic optic neuropathy due to, (Clinical Volume 2, Chapter 5) 
open-globe injury, in children, (Clinical Volume 6, Chapter 81) 
orbital decompression and, (Clinical Volume 2, Chapter 36) 
perforating injury
after reoperation of extraocular muscles, (Clinical Volume 6, Chapter 98) 
needle-delivered anesthesia, (Clinical Volume 6, Chapter 1) 
phthisis bulbi. (See Phthisis bulbi)
restriction, after extraocular muscle surgery, reoperation, (Clinical Volume 6, Chapter 98) 
Globoid cell leukodystrophy. See Krabbe’s disease
Glomerulonephritis, membranoproliferative, type II, (Clinical Volume 5, Chapter 31) 
Glucocorticoids, (Foundations Volume 3, Chapter 31) See also Corticosteroids
general considerations, (Foundations Volume 3, Chapter 31) 
mechanism of action, (Foundations Volume 3, Chapter 31) 
subconjunctival injections of, (Foundations Volume 3, Chapter 23) 
Glucose
corneal metabolism of, (Foundations Volume 2, Chapter 4) 
effect on retinal blood flow, (Foundations Volume 2, Chapter 5) 
lenticular metabolism, (Foundations Volume 2, Chapter 10) 
transport mechanisms, in lens, (Foundations Volume 2, Chapter 10) 
Glucose levels, in diabetes, retinopathy and, (Clinical Volume 3, Chapter 30) 
Glucose-6-phosphate dehydrogenase deficiency, congenital hemolytic jaundice, (Clinical Volume 5, Chapter 41) 
Glucosylceramide lipidosis (Gaucher disease), (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 54B) 
Glutamate
excitotoxicity, in glaucoma, (Clinical Volume 3, Chapter 57) 
and retinal ganglion cells, (Clinical Volume 3, Chapter 57) 
in retinal neurotransmission, (Foundations Volume 1, Chapter 20) 
vitreal, and glaucoma, (Clinical Volume 3, Chapter 52) 
Glutamate receptors
agonists, for glaucoma, (Clinical Volume 3, Chapter 57) 
antagonists, for glaucoma, (Clinical Volume 3, Chapter 57) 
overactivation, and glaucoma, (Clinical Volume 3, Chapter 57) 
Glyceraldehyde-3-phosphate dehydrogenase, and apoptotic signaling, (Clinical Volume 3, Chapter 57) 
Glycerin, in glaucoma
acute angle-closure, (Clinical Volume 3, Chapter 53) 
systemic toxicity, (Clinical Volume 5, Chapter 37) 
Glycerine, for glaucoma, (Clinical Volume 3, Chapter 52) 
Glycerol, as hyperosmotic agent, (Foundations Volume 2, Chapter 7) (Foundations Volume 3, Chapter 28) 
for glaucoma, (Clinical Volume 3, Chapter 56) 
dosage and administration of, (Clinical Volume 3, Chapter 56) 
systemic adverse effects of, (Clinical Volume 3, Chapter 56) 
Glycine, retinopathy due to, (Clinical Volume 2, Chapter 5) 
Glycogen, in iris pigment epithelium, (Foundations Volume 1, Chapter 11) 
Glycogen storage disease
type I, (Clinical Volume 4, Chapter 15) (Clinical Volume 5, Chapter 19) See also Von Gierke’s disease
Glycogen storage diseases, perimacular retinal deposits in, (Clinical Volume 5, Chapter 30) 
Glycolipid lipidosis. See Fabry’s disease
Glycolipids, host surface, bacterial receptors and, (Foundations Volume 2, Chapter 52) 
Glycosphingolipid lipidosis. See Fabry’s disease
Glyrol. See Glycerol
Goblet cells, (Foundations Volume 2, Chapter 2) 
conjunctival goblet cell secretion, (Foundations Volume 2, Chapter 2) 
functional anatomy, (Foundations Volume 2, Chapter 2) 
signaling pathways, (Foundations Volume 2, Chapter 2) 
Gold-198, ocular toxicity, (Clinical Volume 5, Chapter 37) 
Goldman kinetic perimetry, (Clinical Volume 2, Chapter 10) 
Goldmann applanation tonometry, (Foundations Volume 2, Chapter 7) 
Goldmann equation, (Clinical Volume 3, Chapter 56) 
Goldmann-Favre disease, (Clinical Volume 3, Chapter 39) 
Goldmann goniolens, (Clinical Volume 1, Chapter 62) 
Goldmann three-mirror lens
in slit lamp biomicroscopy, optic disc hypoplasia, (Clinical Volume 2, Chapter 5) 
Gold salts, side effects and toxicity
Gold sodium thiomalate, ocular toxicity, (Clinical Volume 5, Chapter 37) 
Gold-weight implantation, for facial nerve paralysis, (Clinical Volume 5, Chapter 88) 
Golf, eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45) 
Goltz syndrome (focal dermal hypoplasia), (Foundations Volume 3, Chapter 59) 
Goniophotocoagulation, (Clinical Volume 6, Chapter 19) 
Gonioscopy, (Clinical Volume 1, Chapter 62)  (Clinical Volume 3, Chapter 44 ) 
angle classification systems for, (Clinical Volume 3, Chapter 44) 
for angle grading, (Clinical Volume 3, Chapter 44) 
blood vessels in angle and, (Clinical Volume 3, Chapter 44) 
geometric optics and, (Clinical Volume 3, Chapter 44) 
in glaucoma
glaucoma and, pigmentary, (Clinical Volume 3, Chapter 54B) 
Goldmann three-mirror lens in, (Clinical Volume 3, Chapter 44) 
indications and techniques for, (Clinical Volume 3, Chapter 44) 
lens cleaning for, (Clinical Volume 3, Chapter 44) 
in narrow-angled eye evaluation, (Clinical Volume 3, Chapter 44) 
in pediatric patient, (Clinical Volume 3, Chapter 51) 
in peripheral anterior chamber depth estimating, (Clinical Volume 3, Chapter 44) 
Schwalbe’s line, (Clinical Volume 3, Chapter 44) 
in surgery, for acute angle-closure glaucoma, (Clinical Volume 3, Chapter 53) 
Goniosynechiolysis, (Clinical Volume 3, Chapter 53) 
in uveitic glaucoma, (Clinical Volume 3, Chapter 54D) 
Goniotomy, (Clinical Volume 3, Chapter 51) 
in uveitic glaucoma of juvenile rheumatoid arthritis, (Clinical Volume 3, Chapter 54D) 
Gore-Tex. See Polytetrafluoroethylene (PTFE)
Gorlin-Chaudhry-Moss syndrome, (Foundations Volume 1, Chapter 41) 
Gorlin-Goltz syndrome, basal cell carcinoma associated with, (Clinical Volume 4, Chapter 3) 
GPIC (guinea pig inclusion conjunctivitis), (Foundations Volume 2, Chapter 77) 
Graether collar button hook, (Clinical Volume 6, Chapter 3) 
Grafts. See also See Allografts; Transplantation
patch
scleral, double-plate shunt placement and, (Clinical Volume 6, Chapter 17) 
in penetrating keratoplasty
primary graft failure, (Clinical Volume 6, Chapter 26) 
prognosis for clarity, 2, (Clinical Volume 6, Chapter 26) 
scleral
double-plate shunt placement and, (Clinical Volume 6, Chapter 17) 
skin. (See Skin grafts)
Gramcidin, polymyxin and, (Foundations Volume 3, Chapter 39) 
Gramicidin, in eyedrops, (Clinical Volume 4, Chapter 26) 
Gram-negative anaerobic rods, Actinomyces, (Foundations Volume 2, Chapter 60 ) 
Gram-negative pathogens, infectious endophthalmitis and, (Foundations Volume 2, Chapter 48) 
Gram-positive bacteria, defined, (Foundations Volume 2, Chapter 49) 
Gram stain, (Foundations Volume 2, Chapter 40) See also Gram–negative cocci; Gram–positive aerobic rods; Gram–positive bacteria; Gram–positive cocci, (Clinical Volume 4, Chapter 6) (Clinical Volume 4, Chapter 18) (Foundations Volume 2, Chapter 40) 
Granular cell tumor (myoblastoma), (Clinical Volume 4, Chapter 10) 
Granular dystrophy, (Clinical Volume 4, Chapter 16) See Allografts
superficial keratectomy in, (Clinical Volume 6, Chapter 28) 
superficial variant, (Foundations Volume 3, Chapter 63) 
Granulation tissue, 2, (Foundations Volume 3, Chapter 6) 
Granulocytes, in immune response, (Clinical Volume 4, Chapter 2) 
Granuloma. See also Inflammation, granulomatous
caseating, in tuberculosis, (Clinical Volume 4, Chapter 58) 
cholesterol. (See also Cholesteatoma)
of lacrimal fossa, (Clinical Volume 2, Chapter 24) 
conjunctival. (See also Parinaud’s oculoglandular conjunctivitis)
eosinophilic. (See also Histiocytosis X)
of lacrimal fossa, (Clinical Volume 2, Chapter 24) 
necrobiotic, palisading, (Clinical Volume 2, Chapter 39) 
sarcoid. (See Sarcoidosis)
in toxoplasmosis, (Clinical Volume 4, Chapter 46) 
xanthogranuloma. (See Xanthogranuloma)
Granuloma annulare, (Foundations Volume 3, Chapter 4) 
Granuloma inguinale, (Clinical Volume 4, Chapter 22) 
Granulomatosis
chronic, familial, of childhood, (Foundations Volume 3, Chapter 4) 
Erdheim-Chester disease, (Clinical Volume 2, Chapter 35) 
familial juvenile systemic, (Clinical Volume 5, Chapter 26) 
Wegener’s. (See Wegener’s granulomatosis)
Granulomatous diseases. See also specific disease
orbital, systemic disease causing, (Clinical Volume 2, Chapter 35 ) 
Granuloma venereum, (Clinical Volume 4, Chapter 22) 
Graphical image location, (Clinical Volume 1, Chapter 30) 
Graphical vector method, (Clinical Volume 1, Chapter 30) 
surgically induced change in corneal power and, (Clinical Volume 1, Chapter 30) 
Gratings
in contrast sensitivity testing, (Foundations Volume 2, Chapter 17) 
visibility of
cut-off frequency, (Clinical Volume 1, Chapter 10) 
Graves’ disease, (Clinical Volume 5, Chapter 21) See also Ophthalmopathy, thyroid–associated; Thyroid disorders; (Foundations Volume 2, Chapter 35) See also Thyroid ophthalmopathy
chemodenervation in, (Clinical Volume 6, Chapter 89) 
extraocular muscle evaluations, (Foundations Volume 3, Chapter 17) 
extraocular muscles, (Clinical Volume 2, Chapter 35) 
eye movements in, (Clinical Volume 2, Chapter 12) 
laboratory investigation, (Clinical Volume 2, Chapter 36) 
myasthenia gravis and, (Clinical Volume 1, Chapter 20) 
ophthalmopathy of, (Clinical Volume 1, Chapter 20) 
orbital manifestations of, (Foundations Volume 3, Chapter 17) 
stimulatory antibody in, (Clinical Volume 4, Chapter 34) 
systemic manifestations of, (Foundations Volume 3, Chapter 17) 
trochlear palsy in, (Clinical Volume 2, Chapter 12) 
Gravitational lines, lid, (Foundations Volume 1, Chapter 5) 
Graying of macula, disorders with, (Clinical Volume 2, Chapter 5) 
Grayscale (symbols) display, (Clinical Volume 2, Chapter 10) 
Grayson-Wilbrandt dystrophy, (Clinical Volume 4, Chapter 16) 
Greater superficial petrosal nerve, (Clinical Volume 2, Chapter 40) 
Greenbaum anesthesia cannula, (Clinical Volume 6, Chapter 1) 
Greig syndrome, (Clinical Volume 6, Chapter 110) See also Craniofacial anomalies
Griscelli syndrome, (Clinical Volume 4, Chapter 38) 
Griseofulvin, ocular toxicity, (Clinical Volume 5, Chapter 37) 
Groenouw corneal dystrophy
Gronblad-Strandberg syndrome, (Clinical Volume 5, Chapter 27) 
Growth
regeneration and, in parasympathetic nervous system, (Foundations Volume 2, Chapter 9) 
Growth factors
retinal ganglion cells in glaucoma and, (Clinical Volume 3, Chapter 57) 
Growth factors, stimulation of protein secretion by, (Foundations Volume 2, Chapter 2A) 
Growth hormone
diabetic retinopathy and, (Clinical Volume 3, Chapter 30) 
Growth of eye, intraocular lens power and, for children, (Clinical Volume 6, Chapter 101) 
Guanethidine, ocular toxicity, (Clinical Volume 5, Chapter 37) 
Guanethidine (Ismelin)
effect on aqueous humor, (Foundations Volume 3, Chapter 29) 
effect on catecholamine systems, (Foundations Volume 3, Chapter 29) 
effect on ocular blood flow, (Foundations Volume 2, Chapter 5) 
Guanine monophosphate, cyclic
retinal degeneration and, (Foundations Volume 2, Chapter 12) 
in visual transduction, (Foundations Volume 2, Chapter 12) 
Guarded filtration procedures, (Clinical Volume 6, Chapter 15 ) 
Guillain-Barre syndrome, (Foundations Volume 1, Chapter 36) (Foundations Volume 1, Chapter 37) 
bulbar variant, oculomotor palsy in, (Clinical Volume 2, Chapter 12) 
facial nerve in, (Clinical Volume 2, Chapter 8) 
optic neuritis in, (Clinical Volume 2, Chapter 5) 
Guinea pig inclusion conjunctivitis (GPIC), (Foundations Volume 2, Chapter 77) 
Gullstrand equation, (Clinical Volume 1, Chapter 33) 
Gullstrand schematic eye, (Clinical Volume 1, Chapter 33) 
Gummas, in syphilis, (Clinical Volume 4, Chapter 22) 
Gundersen technique, (Clinical Volume 6, Chapter 33) 
Gunn pupillary reflex. See Pupil of eye, light reflex
Guns
air, eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45) 
BB, eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45) 
Gustatory-lacrimal reflex. See Crocodile tears
Gustatory tearing, (Clinical Volume 2, Chapter 8) 
GVHD. See Graft-versus-host disease
Gyrate atrophy, (Clinical Volume 3, Chapter 24) (Clinical Volume 3, Chapter 25) (Foundations Volume 3, Chapter 54A) 
choroideremia versus, (Clinical Volume 3, Chapter 25A) 
differential diagnosis, (Clinical Volume 3, Chapter 25) 
fluorescein angiography, (Foundations Volume 2, Chapter 113B) 
metabolic findings, (Clinical Volume 3, Chapter 25) 
ophthalmic findings, (Clinical Volume 3, Chapter 25) 
pathologic findings, (Clinical Volume 3, Chapter 25) 
peripheral nervous system in, (Clinical Volume 3, Chapter 25) 
phosphocreatine deficiency hypothesis in, (Clinical Volume 3, Chapter 25) 
retinal degeneration in, pathophysiology, (Clinical Volume 3, Chapter 25) 
skeletal muscle in, (Clinical Volume 3, Chapter 25) 
systemic findings, (Clinical Volume 3, Chapter 25) 

 Back to Top

Subject Index H
HAART therapy (highly active anti-retroviral therapy), for HIV disease, (Foundations Volume 3, Chapter 37) 
Haemophilus. See Hemophilus
Haemophilus influenzae, (Foundations Volume 2, Chapter 40A) 
Haemophilus influenzae, bleb-related infection, (Clinical Volume 4, Chapter 55) 
Hahzaki-Wesenberg bodies, (Foundations Volume 3, Chapter 4) 
Hair follicle tumors, (Clinical Volume 4, Chapter 3) 
Halberg tonometer, (Clinical Volume 3, Chapter 46) 
Haller layer, of choroid, (4)31: 8
Hallermann-Streiff-Francois syndrome, (Clinical Volume 5, Chapter 41) (Clinical Volume 5, Chapter 41) 
Hallervorden-Spatz disease, (Foundations Volume 3, Chapter 13) 
Haller-Zinn circle, (Foundations Volume 1, Chapter 34) 
Hallpike-Dix test, (Clinical Volume 2, Chapter 18) 
Halo
optical derivation, (Clinical Volume 1, Chapter 31) 
parafoveal, in Niemann-Pick disease, (Clinical Volume 3, Chapter 29) 
Haloperidol, ocular toxicity, (Clinical Volume 5, Chapter 37) 
Halothane (Fluothane), epinephrine and, (Foundations Volume 3, Chapter 43) 
Haltia-Santavuori disease, (Clinical Volume 5, Chapter 19) 
Hamartomas, (Foundations Volume 3, Chapter 2) 
astrocytic
retinal, fluorescein angiography, (Foundations Volume 2, Chapter 113A) 
tuberous sclerosis and, (Foundations Volume 3, Chapter 2) 
choroidal, neurofibromatosis and, (Foundations Volume 3, Chapter 2) 
growth pattern of, (Clinical Volume 2, Chapter 42) 
hereditary, disseminated. (See Phakomatoses)
intracranial, in tuberous sclerosis, (Clinical Volume 5, Chapter 36) 
in von Hippel-Lindau disease, (Clinical Volume 3, Chapter 34) 
Hand, anomalies of, and Duane retraction syndrome, (Clinical Volume 1, Chapter 20) 
Handball
eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45) 
team, eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45) 
Hand comparison, in field function test, (Clinical Volume 2, Chapter 2) 
Handicap
occupational ophthalmology and, (Clinical Volume 5, Chapter 47) 
participation versus, (Clinical Volume 5, Chapter 51) 
Handmann anomaly, (Clinical Volume 5, Chapter 31) 
Hanger-Rose test, (Clinical Volume 4, Chapter 4) 
Hansen disease, (Clinical Volume 5, Chapter 63) See also Leprosy
Haptic materials, for lenses, (Clinical Volume 6, Chapter 11) 
Harada syndrome, fluorescein angiography, (Clinical Volume 4, Chapter 57) 
Hard contact lenses. See Contact lenses
Hardy-Rand-Rittler plates, in color vision testing, (Clinical Volume 2, Chapter 2) 
Hashimoto thyroiditis, (Clinical Volume 2, Chapter 35) 
Hashish, ocular toxicity, (Clinical Volume 5, Chapter 37) 
Hazard assessment, occupational ophthalmology and, (Clinical Volume 5, Chapter 47) 
Headache in children, 44–46
pediatric migraine, 45
pediatric pseudotumor cerebri, 45–46
Headaches, (Clinical Volume 2, Chapter 16 ) 
arteriovenous malformation and, (Clinical Volume 2, Chapter 16) 
carotid dissection and, (Clinical Volume 2, Chapter 16) 
differential diagnosis, (Clinical Volume 2, Chapter 16) 
in intracranial mass lesions, (Clinical Volume 2, Chapter 16) 
medication-overuse, (Clinical Volume 2, Chapter 16) 
migraine. (See Migraine)
migraine, hallucinations associated with, (Foundations Volume 2, Chapter 22) 
muscle contraction, (Clinical Volume 2, Chapter 16) 
ocular lesions causing, (Clinical Volume 2, Chapter 16) 
paroxysmal hemicrania, (Clinical Volume 2, Chapter 16) 
in pituitary apoplexy, (Clinical Volume 2, Chapter 6) 
in pseudotumor cerebri, (Clinical Volume 2, Chapter 5) 
Headforms, for protective devices, (Clinical Volume 5, Chapter 45) 
Head oscillations, in congenital nystagmus, (Clinical Volume 2, Chapter 11) 
Head posture
anomalous
correction, in nystagmus, (Clinical Volume 6, Chapter 95 ) 
postoperative, reoperation for, (Clinical Volume 6, Chapter 98) 
in Brown syndrome, (Clinical Volume 1, Chapter 20) 
in congenital fibrosis of inferior rectus muscle, (Clinical Volume 1, Chapter 20) 
in dissociated strabismus complex, (Clinical Volume 1, Chapter 18) 
in Duane retraction syndrome, (Clinical Volume 1, Chapter 20) 
in generalized fibrosis syndrome, (Clinical Volume 1, Chapter 20) 
in strabismus fixus, (Clinical Volume 1, Chapter 20) 
in thyrotoxicosis ophthalmoplegia, (Clinical Volume 1, Chapter 20) 
Head-shaking nystagmus test, vestibulo-ocular reflex, (Clinical Volume 2, Chapter 18) 
Head thrust test, vestibulo-ocular reflex, (Clinical Volume 2, Chapter 18) 
Head tilt, in dissociated strabismus complex, (Clinical Volume 1, Chapter 18) 
Head trauma. See Trauma
Healon/Healon GV. See Viscoelastic materials
Health economics, (Clinical Volume 5, Chapter 69 ) 
cost-benefit analysis in, (Clinical Volume 5, Chapter 69) 
cost-effectiveness analysis in, (Clinical Volume 5, Chapter 69) 
cost-utility analysis in, 4, (Clinical Volume 5, Chapter 69) 
evaluation in
analytic techniques for, (Clinical Volume 5, Chapter 69) 
law of diminishing marginal utility in, (Clinical Volume 5, Chapter 69) 
in ophthalmology, (Clinical Volume 5, Chapter 69) 
resource allocation in, (Clinical Volume 5, Chapter 69) 
Hearing loss. See also Deafness
Duane retraction syndrome and, (Clinical Volume 1, Chapter 20) 
in Meniere’s disease, (Clinical Volume 2, Chapter 18) 
sensorineural, congenital, ocular albinism and, (Clinical Volume 4, Chapter 38) 
Heart. See Cardiovascular disorders
Heart disease, acquired, ocular abnormalities, (Clinical Volume 5, Chapter 22) 
aortic arch syndrome, (Clinical Volume 5, Chapter 22) 
infective endocarditis, (Clinical Volume 5, Chapter 22) 
mitral valve prolapse, (Clinical Volume 5, Chapter 22) 
nonbacterial thrombotic endocarditis, (Clinical Volume 5, Chapter 22) 
Heat phototoxicity, (Clinical Volume 4, Chapter 31) 
Heat-shock proteins, neuroprotective effect, in glaucoma, (Clinical Volume 3, Chapter 52) (Clinical Volume 3, Chapter 56) 
Heat stress proteins, neuroprotection of axons and, (Clinical Volume 3, Chapter 57) 
Heavy-chain disease, hyperviscosity retinopathy in, (Clinical Volume 5, Chapter 23) 
Heavy metal antagonist, ocular toxicity, (Clinical Volume 5, Chapter 37) 
HECC (Hockey Equipment Certification Council), (Clinical Volume 5, Chapter 45) 
Heidelberg retina tomograph, (Foundations Volume 2, Chapter 111) 
visual field indices versus, (Foundations Volume 2, Chapter 111) 
Heijl-Krakau method, (Foundations Volume 2, Chapter 109) 
Heimann-Bielschowsky phenomenon, (Clinical Volume 2, Chapter 13) 
Helicobacter pylori, lymphoma and, (Clinical Volume 2, Chapter 39) 
Helicoidal peripapillary chorioretinal degeneration, (Clinical Volume 4, Chapter 66) 
Helioid choroiditis, unifocal, (Clinical Volume 4, Chapter 49) 
Helmets. See Sports medicine, protective devices
Helmholz schematic eye, (Clinical Volume 1, Chapter 33) 
Helminthic disease(es). See specific disease
Helper T cells, (Clinical Volume 4, Chapter 2) 
in corneal graft rejection, (Clinical Volume 4, Chapter 2) 
toxoplasmosis and, (Clinical Volume 4, Chapter 46) 
Hemagglutination groups, in adenovirus classification, (Foundations Volume 2, Chapter 96) 
Hemagglutination inhibition test, in viral infection diagnosis, (Foundations Volume 2, Chapter 88) 
Hemagglutination test, in toxoplasmosis, (Clinical Volume 4, Chapter 46) 
Hemangioendothelioma, malignant, (Clinical Volume 2, Chapter 37) 
clinical features, (Clinical Volume 2, Chapter 37) 
differential diagnosis, (Clinical Volume 2, Chapter 37) 
management natural history, (Clinical Volume 2, Chapter 37) 
Hemangioendothelioma, orbital, (Clinical Volume 2, Chapter 27) 
Hemangioma, (Foundations Volume 3, Chapter 7) (Clinical Volume 5, Chapter 27) See also Angioma
conjunctival, in Sturge-Weber syndrome, (Clinical Volume 5, Chapter 36) 
corticosteroids in, (Foundations Volume 3, Chapter 31) 
episcleral, (Clinical Volume 4, Chapter 23) 
in Sturge-Weber syndrome, (Clinical Volume 5, Chapter 36) 
Hemangioma, epithelioid, (Clinical Volume 2, Chapter 37) 
clinical features, (Clinical Volume 2, Chapter 37) 
differential diagnosis, (Clinical Volume 2, Chapter 37) 
Hemangiomatosis, cutaneovisceral, (Clinical Volume 2, Chapter 17) 
Hematocrit, ischemic optic neuropathy and, (Clinical Volume 2, Chapter 5) 
Hematologic disorders, (Clinical Volume 5, Chapter 23) See also specific disorders
coagulation disorders, (Clinical Volume 5, Chapter 23) 
cotton-wool spots and. (See also Cotton-wool spots)
diabetic retinopathy and, (Clinical Volume 3, Chapter 30) 
hemostasis disorders, (Clinical Volume 5, Chapter 23) 
platelet disorders, (Clinical Volume 5, Chapter 23) 
reactive lymphoid hyperplasia, (Clinical Volume 5, Chapter 23) 
retinal changes in, (Clinical Volume 3, Chapter 18 ) 
Hematologic reactions, NSAIDs and, (Foundations Volume 3, Chapter 38) 
Hematoxylin staining, (Foundations Volume 2, Chapter 40) 
Hemeralopia
with progressive cone-rod dystrophies, (Clinical Volume 3, Chapter 9) 
with rod monochromaticism, (Clinical Volume 3, Chapter 9) 
Hemianopia, (Foundations Volume 2, Chapter 22) See also Blindsight
altitudinal
in ischemic optic neuropathy, (Clinical Volume 2, Chapter 5) 
in retinal arterial occlusion, (Clinical Volume 2, Chapter 5) 
bitemporal
in chiasmal syndrome, (Clinical Volume 2, Chapter 6) 
in craniopharyngioma, (Clinical Volume 2, Chapter 6) 
homonymous, (Clinical Volume 2, Chapter 2) 
in occipital apoplexy, (Clinical Volume 2, Chapter 17) 
optokinetic nystagmus and, (Clinical Volume 2, Chapter 3) 
striate lesions and, (Clinical Volume 2, Chapter 7) 
visual field testing in, (Foundations Volume 2, Chapter 17) 
incomplete, bilateral, (Clinical Volume 2, Chapter 7) 
macula-splitting, (Clinical Volume 2, Chapter 7) 
in optic radiation lesions, (Clinical Volume 2, Chapter 7) 
in optic tract lesions, (Clinical Volume 2, Chapter 7) 
in pituitary adenoma, (Clinical Volume 2, Chapter 6) 
with sparing of monocular temporal crescent, (Clinical Volume 2, Chapter 7) 
unilateral, in infants, (Clinical Volume 2, Chapter 13) 
Hemianopic scotoma
Hemiatrophy, facial. See Parry-Romberg syndrome
Hemicrania, paroxysmal, (Clinical Volume 2, Chapter 16) 
Hemidyschromatopsia, (Clinical Volume 2, Chapter 7) 
Hemifield analysis, in field defect identification, (Clinical Volume 3, Chapter 49) 
Hemifield slide, (Clinical Volume 2, Chapter 7) 
Hemiplegia, in migraine, (Clinical Volume 2, Chapter 16) 
Hemi-scotomata, central, (Clinical Volume 2, Chapter 7) 
Hemi-see-saw nystagmus, (Foundations Volume 1, Chapter 38) 
Hemodialysis. See also Dialysis
ocular complications, (Clinical Volume 5, Chapter 31) 
Hemoglobin, laser photocoagulation and, (Clinical Volume 6, Chapter 76) 
Hemoglobinopathies, (Clinical Volume 3, Chapter 17) See also Sickle cell disease
Hemolytic glaucoma, (Clinical Volume 3, Chapter 54E) 
Hemolytic-uremic syndrome, (Clinical Volume 5, Chapter 31) 
Hemophilus aegyptus, corneal ulcers, (Clinical Volume 4, Chapter 18) 
Hemophilus influenzae
biotype III, conjunctivitis and, (Clinical Volume 4, Chapter 5) 
Hemophilus influenzae, conjunctivitis, treatment, (Foundations Volume 3, Chapter 36) 
Hemorrhage(s). See also Bleeding
anterior chamber, during cataract extraction, (Foundations Volume 3, Chapter 6) 
in arteriovenous malformations, (Clinical Volume 2, Chapter 17) 
as complication of rectus muscle surgery, (Clinical Volume 6, Chapter 83) 
flame, in chronic glaucoma, (Clinical Volume 2, Chapter 5) 
with hyaline bodies, (Clinical Volume 2, Chapter 5) 
in hypertensive retinopathy, (Clinical Volume 3, Chapter 13) 
intraocular
after vitreous surgery, for proliferative vitreoretinopathy, (Clinical Volume 6, Chapter 58) 
during diabetic vitrectomy, (Clinical Volume 6, Chapter 57) 
intrastromal, deep stromal neovascularization and, contact lens-associated, (Clinical Volume 4, Chapter 27) 
optic disc, and glaucoma, (Clinical Volume 3, Chapter 52) 
in pars planitis, (Clinical Volume 4, Chapter 43) 
perivascular, in acute retinal necrosis syndrome, (Clinical Volume 3, Chapter 28) 
in pituitary adenoma, (Clinical Volume 2, Chapter 6) 
premacular, dense, vitrectomy for, (Clinical Volume 6, Chapter 57) 
recurrent, after diabetic vitrectomy, (Clinical Volume 6, Chapter 57) 
retrobulbar, needle-delivered anesthesia, (Clinical Volume 6, Chapter 1) 
secondary IOL implantation, (Clinical Volume 6, Chapter 8) 
in sickle cell retinopathy, (Clinical Volume 3, Chapter 17) 
splinter, in glaucoma, (Clinical Volume 3, Chapter 52) 
subarachnoid, childhood aneurysms and, (Clinical Volume 2, Chapter 17) 
subfoveal, vitrectomy for, (Clinical Volume 6, Chapter 56) 
subhyaloid, vitrectomy for, (Clinical Volume 6, Chapter 56) 
subpigment epithelium, (Clinical Volume 3, Chapter 7) 
subretinal, (Clinical Volume 3, Chapter 7) 
choroidal rupture and, (Clinical Volume 3, Chapter 31) 
in pathologic myopia, (Clinical Volume 3, Chapter 36) 
suprachoroidal
after cataract surgery, (Clinical Volume 3, Chapter 54G) 
differential diagnosis, (Clinical Volume 3, Chapter 53) 
glaucoma surgery and, (Clinical Volume 6, Chapter 24) 
massive, vitrectomy-related, (Clinical Volume 6, Chapter 56) 
trauma to iris and, (Clinical Volume 4, Chapter 61) 
Hemorrhagic conjunctivitis, acute, (Foundations Volume 2, Chapter 92 ) 
Hemorrhagic detachment, retinal pigment epithelium, optical coherence tomography, (Foundations Volume 2, Chapter 107) 
Hemorrhagic disorders, albinism-hemorrhagic diathesis, (Clinical Volume 4, Chapter 38) 
Hemorrhagic infarction, retinal, (Foundations Volume 3, Chapter 13) 
Hemorrhagic macular dystrophy, hereditary, (Foundations Volume 3, Chapter 60) 
fluorescein angiography, (Foundations Volume 2, Chapter 113B) 
Hemorrhagic retinopathy, (Foundations Volume 3, Chapter 13) 
Hemosiderosis, ocular, (Clinical Volume 3, Chapter 7) 
Hemosiderosis bulbi, (Foundations Volume 3, Chapter 6) 
Hemosiderotic glaucoma, (Clinical Volume 3, Chapter 54E) 
Henle
fiber layer of. (See Outer plexiform layer (OPL))
fiber layer of, retinal, (Clinical Volume 3, Chapter 1) 
Henle-Koch postulate, (Foundations Volume 2, Chapter 43) 
Heparin
characteristics of, (Foundations Volume 3, Chapter 41) 
diabetic vitrectomy and, (Clinical Volume 6, Chapter 57) 
for thrombophilia, (Clinical Volume 5, Chapter 23) 
Heparin sulfate
catabolism, metabolic blocks, (Clinical Volume 4, Chapter 15) 
Heparin sulfate, vitreous, (Foundations Volume 1, Chapter 16) 
Hepatic disease. See Liver, disease
Hepatitis, viral, (Clinical Volume 5, Chapter 30) 
Hepatitis C, corneal ulcers in, interferon for, (Foundations Volume 2, Chapter 101) 
Hepatocyte growth factor
Hepatolenticular degeneration. See Wilson’s disease
Hepatomegaly, central corneal opacification and, (Clinical Volume 5, Chapter 30) 
Herbert pits, in trachoma, (Clinical Volume 5, Chapter 60) 
Hereditary abetalipoproteinemia, (Clinical Volume 3, Chapter 24) 
Hereditary angioedema, (Foundations Volume 2, Chapter 29) 
Hereditary anterior membrane dystrophy, (Clinical Volume 4, Chapter 16) 
Hereditary benign intraepithelial neoplasia, (Foundations Volume 3, Chapter 8) 
Hereditary chorioretinal dystrophies. See specific type
Hereditary endothelial dystrophy, late, (Clinical Volume 4, Chapter 16) 
Hereditary epithelial dystrophy, (Clinical Volume 4, Chapter 16) 
Hereditary factors. See also Chromosome abnormalities; Genetics
in benign concentric annular macular dystrophy, (Clinical Volume 3, Chapter 9) 
in bullous pemphigoid, (Clinical Volume 5, Chapter 27) 
in butterfly-shaped pigment dystrophy of fovea, (Clinical Volume 3, Chapter 9) 
in central areolar choroidal dystrophy, (Clinical Volume 3, Chapter 9) 
in choroideremia, (Clinical Volume 3, Chapter 2) 
in cone monochromaticism, (Clinical Volume 3, Chapter 9) 
in craniofacial syndromes, (Clinical Volume 6, Chapter 110) 
in cystoid macular edema, (Clinical Volume 3, Chapter 9) 
in drusen of optic disc, (Clinical Volume 2, Chapter 5) 
in Fabry’s disease, (Clinical Volume 3, Chapter 29) 
in familial drusen, (Clinical Volume 3, Chapter 9) 
in familial foveal retinopathy, (Clinical Volume 3, Chapter 9) 
in fenestrated sheen macular dystrophy, (Clinical Volume 3, Chapter 9) 
in foveomacular vitelliform dystrophy, (Clinical Volume 3, Chapter 9) 
in fundus flavimaculatus, (Clinical Volume 3, Chapter 9) 
in Graves’ disease, (Clinical Volume 2, Chapter 36) 
in hereditary macular dystrophy, (Clinical Volume 3, Chapter 9) 
in macroreticular dystrophy of retinal pigment epithelium, (Clinical Volume 3, Chapter 9) 
in North Carolina macular dystrophy, (Clinical Volume 3, Chapter 9) 
in oculorenal syndromes, (Clinical Volume 5, Chapter 31) 
in optic atrophies, degenerative, (Clinical Volume 2, Chapter 5 ) 
in optic disc hypoplasia, (Clinical Volume 2, Chapter 5) 
in pattern dystrophy of pigment epithelium, (Clinical Volume 3, Chapter 9) 
in pericentral rod-cone dystrophy, (Clinical Volume 3, Chapter 9) 
in pigment epithelial dystrophy, (Clinical Volume 3, Chapter 9) 
in progressive cone-rod dystrophies, (Clinical Volume 3, Chapter 9) 
in retinal dystrophies, (Clinical Volume 3, Chapter 2) 
in rod monochromaticism, (Clinical Volume 3, Chapter 9) 
in sickle cell disease, (Clinical Volume 3, Chapter 17) 
in Sjorgren’s reticular dystrophy of retinal pigment epithelium, (Clinical Volume 3, Chapter 9) 
in Stargardt’s disease, (Clinical Volume 3, Chapter 9) 
in thyroid orbitopathy, (Clinical Volume 2, Chapter 36) 
in vitelliform dystrophy, (Clinical Volume 3, Chapter 9) 
in X-linked juvenile retinoschisis, (Clinical Volume 3, Chapter 9) 
Hereditary hemorrhagic macular dystrophy, (Clinical Volume 3, Chapter 9) 
Hereditary hyperferritinemia-cataract syndrome, (Clinical Volume 5, Chapter 41) 
Hereditary hypertyrosinemia, (Foundations Volume 1, Chapter 9) 
Hereditary macular dystrophies, (Clinical Volume 3, Chapter 9 ) 
autosomal dominant fundus flavimaculatus, (Clinical Volume 3, Chapter 9) 
benign concentric annular macular dystrophy, (Clinical Volume 3, Chapter 9) 
butterfly-shaped pigment dystrophy of fovea, (Clinical Volume 3, Chapter 9) 
central areolar choroidal dystrophy, (Clinical Volume 3, Chapter 9) 
central areolar pigment epithelial dystrophy, (Clinical Volume 3, Chapter 9) 
of choriocapillaris, (Clinical Volume 3, Chapter 9) 
cone dystrophies, (Clinical Volume 3, Chapter 9) 
dominant cystoid macular dystrophy, (Clinical Volume 3, Chapter 9) 
dominant slowly progressive macular dystrophy of Singerman-Berkow-Patz, (Clinical Volume 3, Chapter 9) 
familial drusen, (Clinical Volume 3, Chapter 9) 
familial foveal retinoschisis, (Clinical Volume 3, Chapter 9) 
fenestrated sheen macular dystrophy, (Clinical Volume 3, Chapter 9) 
foveomacular vitelliform dystrophy, (Clinical Volume 3, Chapter 9) 
fundus flavimaculatus, (Clinical Volume 3, Chapter 9) 
genetic testing in, (Clinical Volume 3, Chapter 9) 
historical perspectives on, (Clinical Volume 3, Chapter 9) 
macroreticular dystrophy of retinal pigment epithelium, (Clinical Volume 3, Chapter 9) 
pericentral rod-cone, (Clinical Volume 3, Chapter 9) 
pigment epithelial, (Clinical Volume 3, Chapter 9) 
of retinal pigment epithelium, (Clinical Volume 3, Chapter 9) 
of sensory retina, (Clinical Volume 3, Chapter 9) 
Sjorgren’s reticular dystrophy of retinal pigment epithelium, (Clinical Volume 3, Chapter 9) 
X-linked juvenile retinoschisis, 3, (Clinical Volume 3, Chapter 9) 
Hereditary macular dystrophies. See Macular dystrophy(ies), hereditary
Hereditary mucoepithelial dysplasia, (Clinical Volume 5, Chapter 41) 
Hereditary olivopontocerebellar degeneration, (Foundations Volume 3, Chapter 13) 
Hereditary optic neuropathy, Leber. See Leber’s optic neuropathy
Hereditary stromal dystrophy, congenital, (Clinical Volume 4, Chapter 16) 
Heredity, optical system and, (Clinical Volume 1, Chapter 34) 
Hermann-Opitz syndrome, (Foundations Volume 1, Chapter 41) 
Hermann-Pallister-Opitz syndrome, (Foundations Volume 1, Chapter 41) 
Herniation syndromes, cerebral visual loss in, (Clinical Volume 2, Chapter 7) 
Herpes simplex infections
atopic keratoconjunctivitis and, (Clinical Volume 4, Chapter 2) 
conjunctivitis
phlyctenular keratoconjunctivitis versus, (Clinical Volume 4, Chapter 8) 
cornea in, glaucoma and, (Clinical Volume 3, Chapter 54F) 
dendritic keratitis, (Clinical Volume 4, Chapter 17) 
follicular conjunctival reaction in, (Clinical Volume 4, Chapter 17) 
genital (HSV-II), ophthalmia neonatorum and, (Clinical Volume 4, Chapter 6) 
glaucoma and, 3–4, (Clinical Volume 3, Chapter 54D) 
keratitis. (See Herpes simplex keratitis)
lid vesicles with, (Clinical Volume 4, Chapter 17) 
penetrating keratoplasty and, (Clinical Volume 6, Chapter 26) 
retinitis
necrotizing, toxoplasmic retinochoroiditis versus, (Clinical Volume 4, Chapter 46) 
retinal detachment in, (Clinical Volume 6, Chapter 56) 
Herpes simplex keratitis, (Clinical Volume 4, Chapter 2) (Clinical Volume 4, Chapter 19)  (Clinical Volume 5, Chapter 33) (Foundations Volume 1, Chapter 9) (Foundations Volume 2, Chapter 89) 
in atopic dermatitis, (Clinical Volume 5, Chapter 27) 
corticosteroids in, (Clinical Volume 4, Chapter 19) 
differential diagnosis, (Clinical Volume 4, Chapter 19) 
disciform, (Clinical Volume 4, Chapter 19) 
clinical manifestations, (Clinical Volume 4, Chapter 19) 
diagnosis and differential diagnosis, (Clinical Volume 4, Chapter 19) 
natural course and variations in clinical presentation, (Clinical Volume 4, Chapter 19) 
epithelial, (Clinical Volume 4, Chapter 19) 
clinical manifestations, (Clinical Volume 4, Chapter 19) 
diagnosis and differential diagnosis, (Clinical Volume 4, Chapter 19) 
laboratory investigation, (Clinical Volume 4, Chapter 19) 
natural course and variations in clinical presentation, (Clinical Volume 4, Chapter 19) 
in stromal keratitis, (Clinical Volume 4, Chapter 19) 
necrotizing, stromal, (Clinical Volume 4, Chapter 19) 
primary, (Clinical Volume 4, Chapter 19) 
clinical manifestations, (Clinical Volume 4, Chapter 19) 
diagnosis and differential diagnosis, (Clinical Volume 4, Chapter 19) 
laboratory investigations, (Clinical Volume 4, Chapter 19) 
natural course and variations in clinical presentation, (Clinical Volume 4, Chapter 19) 
viral replicative cycle, (Clinical Volume 4, Chapter 19) 
virus in. (See Herpes simplex virus)
virus isolation in, (Clinical Volume 4, Chapter 19) 
Herpes simplex virus (HSV), (Foundations Volume 2, Chapter 85) (Foundations Volume 2, Chapter 89) (Foundations Volume 2, Chapter 90)  (Foundations Volume 3, Chapter 7) (Clinical Volume 4, Chapter 19)  (Clinical Volume 5, Chapter 33) 
acute retinal necrosis syndrome and, (Clinical Volume 3, Chapter 28) 
corneal ulcers and, (Foundations Volume 3, Chapter 9) 
development at epithelial site
recurrent disease, breakdown of latency and, (Foundations Volume 2, Chapter 98) 
dissemination or axonal spread of, (Foundations Volume 2, Chapter 98) 
erythema multiforme and, (Clinical Volume 5, Chapter 27) 
host-virus interactions, (Clinical Volume 4, Chapter 19) 
latency, (Foundations Volume 2, Chapter 89) (Foundations Volume 2, Chapter 90) (Foundations Volume 2, Chapter 98) (Clinical Volume 4, Chapter 19) 
breakdown of, and establishment of recurrent disease at epithelial site, (Foundations Volume 2, Chapter 98) 
establishment and maintenance of, (Foundations Volume 2, Chapter 98) 
neuronal and extraneuronal, (Foundations Volume 2, Chapter 89) 
as normal inhabitant of eye, (Foundations Volume 2, Chapter 41) 
recurrent disease and, (1)98: 8–9
replicative cycle, (Clinical Volume 4, Chapter 19) 
corticosteroids and, (Clinical Volume 4, Chapter 19) 
stages of infection, (Foundations Volume 2, Chapter 89) 
Herpes simplex virus retinitis, (Clinical Volume 4, Chapter 45) 
Herpesvirus family, (Clinical Volume 3, Chapter 28) 
Herpes zoster infection, or shingles, (Foundations Volume 1, Chapter 36) 
Herpes zoster ophthalmicus, (Foundations Volume 1, Chapter 36)  (Foundations Volume 2, Chapter 94) (Foundations Volume 3, Chapter 4) (Clinical Volume 4, Chapter 2) (Clinical Volume 4, Chapter 20) See also Varicella–zoster virus (VZV)
acute retinal necrosis syndrome and, (Clinical Volume 3, Chapter 28) 
dendriform keratitis, (Clinical Volume 4, Chapter 17) 
dermatomal considerations in, (Clinical Volume 4, Chapter 20) 
extraocular muscles in, (Clinical Volume 4, Chapter 20) 
keratouveitis in, (Clinical Volume 4, Chapter 39) 
laboratory evaluation of, (Clinical Volume 4, Chapter 20) 
neurologic involvement in, (Clinical Volume 4, Chapter 20) 
ocular involvement in, (Clinical Volume 4, Chapter 20) 
optic neuritis in, (Clinical Volume 2, Chapter 5) 
preseptal cellulitis in, (Clinical Volume 4, Chapter 25) 
systemic work-up in, (Clinical Volume 4, Chapter 20) 
topical anesthesia in, (Foundations Volume 3, Chapter 35) 
Herpes zoster sine herpete, (Foundations Volume 2, Chapter 36) 
Herpetic simplex keratitis, recurrent, prevention of, (Clinical Volume 4, Chapter 19) 
Hertel exophthalmometer, (Clinical Volume 2, Chapter 14) 
Hessburg anterior chamber lenses, (Clinical Volume 6, Chapter 26) 
Hess diplopia screen, (Clinical Volume 2, Chapter 12) 
Hetacillin, systemic toxicity, (Clinical Volume 5, Chapter 37) 
HETE. See Hydroxyeicosatetraenoic acid
Heterochromia
in Fuchs’ syndrome, (Clinical Volume 3, Chapter 54D) 
hemosiderosis and, (Foundations Volume 3, Chapter 6) 
in Horner’s syndrome, (Clinical Volume 2, Chapter 15) 
Heterochromia iridium, (Clinical Volume 4, Chapter 31) 
Heterochromic iridocyclitis of Fuchs, (Clinical Volume 3, Chapter 55) See also Fuchs’ syndrome
Heterogeneity, genetic, (Foundations Volume 3, Chapter 55) 
Heteropia, macular, vitrectomy in, (Clinical Volume 6, Chapter 56) 
Heterozygosity
in gyrate atrophy, (Clinical Volume 3, Chapter 25) 
Hetrazan. See Diethylcarbamazine
Hexachlorophene, in postoperative prophylaxis, (Foundations Volume 2, Chapter 64) 
Hexamethonium, ocular toxicity, (Clinical Volume 5, Chapter 37) 
Hexamidine, in Acanthamoeba keratitis, (Foundations Volume 2, Chapter 66) 
High-density lipoprotein deficiency, familial. See Tangier disease
Higher cortical function, (Clinical Volume 2, Chapter 7) 
Highly active antiretroviral therapy, cataract with, (Clinical Volume 5, Chapter 41) 
Highly active antiretroviral therapy (HAART)
cytomegalovirus and, (Clinical Volume 3, Chapter 28A) 
immune-recovery uveitis in, (Clinical Volume 3, Chapter 28A) 
Hirschberg test, (Clinical Volume 1, Chapter 6) 
Histamine
in allergic rhinoconjunctivitis, (Clinical Volume 4, Chapter 2) 
in tears, in vernal keratoconjunctivitis, (Clinical Volume 4, Chapter 9) 
Histamine receptors, blockage of, in herpes zoster treatment, (Clinical Volume 4, Chapter 20) 
Histiocyte, epithelioid, (Foundations Volume 3, Chapter 1) 
Histiocytes, foamy, in uveitis, 3, (Clinical Volume 4, Chapter 54) 
Histiocytic disorders, (Clinical Volume 2, Chapter 39 ) 
Histiocytosis
Langerhans’ cell, (Clinical Volume 2, Chapter 39) 
sinus, with massive lymphadenopathy, (Clinical Volume 2, Chapter 39) 
Histochemistry
extraocular muscle, (Foundations Volume 1, Chapter 31) 
Histocompatibility antigens (HLA), (Foundations Volume 2, Chapter 38) See also Major histocompatibility complex
in ankylosing spondylitis, (Foundations Volume 2, Chapter 33) 
inflammation and, 2, (Foundations Volume 3, Chapter 3) 
in transplant rejection, (Foundations Volume 2, Chapter 25) 
in Vogt-Koyanagi-Harada syndrome, (Foundations Volume 2, Chapter 38) 
Histocompatibility complex, major. See Major histocompatibility complex (MHC)
Histoplasma capsulatum, biology, (Clinical Volume 4, Chapter 48) 
Histoplasmosis, (Clinical Volume 4, Chapter 48)  (Clinical Volume 5, Chapter 33) (Foundations Volume 2, Chapter 32) (Foundations Volume 3, Chapter 4) 
choroidal neovascular membrane excision, (Clinical Volume 6, Chapter 62) 
clinical features, (Clinical Volume 4, Chapter 48) 
differential diagnosis, (Clinical Volume 4, Chapter 48) 
experimental data, (Clinical Volume 4, Chapter 48) 
geographic distribution, (Clinical Volume 4, Chapter 48) 
historical viewpoint, (Clinical Volume 4, Chapter 48) 
peripapillary neovascularization in, (Clinical Volume 4, Chapter 48) 
photocoagulation in, (Clinical Volume 4, Chapter 48) 
photodynamic therapy in, (Clinical Volume 4, Chapter 48) 
spontaneous recovery in, (Clinical Volume 4, Chapter 48) 
subfoveal membrane removal, 5, (Clinical Volume 6, Chapter 62) 
Histoplasmosis, skin testing, (Foundations Volume 2, Chapter 40A) 
History taking
in ankylosing spondylitis, (Clinical Volume 4, Chapter 40) 
neuro-ophthalmologic, (Clinical Volume 2, Chapter 1 ) 
orbital diseases and, (Clinical Volume 2, Chapter 14 ) 
in scleral disease, (Clinical Volume 4, Chapter 23) 
in trauma, eyelid, (Clinical Volume 5, Chapter 75) 
before vitrectomy, (Clinical Volume 6, Chapter 56) 
Histo spots, in histoplasmosis, (Clinical Volume 4, Chapter 48) 
HIV/AIDS. See also Human immunodeficiency virus (HIV)
atypical mycobacterial infection, (Clinical Volume 4, Chapter 58) 
eye movements in, (Clinical Volume 2, Chapter 12) 
fluorescein angiography in, (Clinical Volume 4, Chapter 57) 
herpes zoster ophthalmicus in, (Clinical Volume 4, Chapter 20) 
highly active antiretroviral therapy (HAART) for, cytomegalovirus and, (Clinical Volume 3, Chapter 28A) 
immune-recovery uveitis in, (Clinical Volume 3, Chapter 28A) 
indicator disease, (Clinical Volume 5, Chapter 33) 
ophthalmic disorders, (Clinical Volume 5, Chapter 33) 
optic neuropathies, (Clinical Volume 2, Chapter 5) 
orbital inflammation, (Clinical Volume 2, Chapter 14) 
progressive outer retinal necrosis syndrome, (Clinical Volume 3, Chapter 28 ) 
retinopathy, cytomegalovirus retinitis versus, (Clinical Volume 3, Chapter 28A) 
saccadic velocity, (Clinical Volume 1, Chapter 21) 
seborrheic blepharitis, 2, (Clinical Volume 4, Chapter 22) 
serologic diagnosis, (Clinical Volume 5, Chapter 33) 
toxoplasmosis, (Clinical Volume 4, Chapter 46) 
polymerase chain reaction, (Clinical Volume 4, Chapter 46) 
serologic diagnosis, (Clinical Volume 4, Chapter 46) 
treatment, (5) 33: 10–11
Hives. See Urticaria
HLA-B27. See also Histocompatibility antigens
in ankylosing spondylitis, (Foundations Volume 2, Chapter 33) 
in Reiter’s syndrome, (Foundations Volume 2, Chapter 33) 
HLA system, 3, (Clinical Volume 4, Chapter 2) (Clinical Volume 4, Chapter 34) 
in acute retinal necrosis syndrome, (Clinical Volume 3, Chapter 28) 
anterior uveitis and, (Clinical Volume 3, Chapter 54D) 
crossmatching, in corneal transplant, (Clinical Volume 4, Chapter 2) 
in dermatitis herpetiformis, (Clinical Volume 5, Chapter 27) 
in diabetic retinopathy, (Clinical Volume 5, Chapter 20) 
joint disease and, (Clinical Volume 3, Chapter 54D) 
in multiple evanescent white dot syndrome, (Clinical Volume 4, Chapter 49) 
in pars planitis, (Clinical Volume 4, Chapter 43) 
in phakic patients with cystoid macular edema, retinal periphlebitis, and vitreous inflammation, (Clinical Volume 4, Chapter 43) 
in presumed ocular histoplasmosis syndrome, (Clinical Volume 4, Chapter 48) 
in sympathetic ophthalmia, (Clinical Volume 4, Chapter 51) 
in thyroid orbitopathy, (Clinical Volume 2, Chapter 36) 
in toxoplasmosis, (Clinical Volume 4, Chapter 46) 
in Vogt-Koyanagi-Harada syndrome, (Clinical Volume 4, Chapter 51) 
Hockey
field, eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45) 
ice, eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45) 
street/floor/rink/ in-line roller, eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45) 
Hockey Equipment Certification Council (HECC), (Clinical Volume 5, Chapter 45) 
Hoffer-Colenbrander formula, (Clinical Volume 1, Chapter 64) 
Holes
macular. (See Macula, holes)
retinal. (See Retina, holes)
Hollenhorst plaque, (Clinical Volume 3, Chapter 7) 
Holmes-Adie syndrome, (Clinical Volume 2, Chapter 15) 
Holthouse-Batten superficial choroiditis, (Clinical Volume 3, Chapter 9) 
Holt-Oram syndrome, and Duane retraction syndrome, (Clinical Volume 1, Chapter 20) 
Homatropine
ocular teratogenicity, (Foundations Volume 1, Chapter 39) 
pupillary effects, (Foundations Volume 2, Chapter 9) 
side effects, in infants and children, (Foundations Volume 3, Chapter 43) 
systemic toxicity, (Clinical Volume 5, Chapter 37) 
Homeostasis, ocular, (Foundations Volume 3, Chapter 1) 
Homer-Wright rosettes, in retinoblastoma, (Clinical Volume 6, Chapter 75) 
Homocysteine, pathway, (Clinical Volume 5, Chapter 23) 
Homogentisic acid oxidase deficiency, (Clinical Volume 4, Chapter 15) 
Homonymous defects, rehabilitation of, (Clinical Volume 2, Chapter 7) 
Homonymous field defects
hemianopia, (Clinical Volume 2, Chapter 1) See also Hemianopia
hemioptic hypoplasia, (Clinical Volume 2, Chapter 5) 
Homoplastic keratomileusis, (Clinical Volume 1, Chapter 64) 
Homozygous, defined, (Foundations Volume 3, Chapter 51) 
Honeycomb choroiditis, (Clinical Volume 3, Chapter 9) 
Honeycomb dystrophy, (Foundations Volume 3, Chapter 63) 
HOOD (hereditary osteo-onychodysplasia), (Clinical Volume 5, Chapter 31) 
Hooper Visual Organization Test, (Clinical Volume 2, Chapter 7) 
Horizontal deviations
in oblique muscle dysfunction, (Clinical Volume 1, Chapter 17) 
Horizontal gaze
brainstem control, (Clinical Volume 2, Chapter 10) 
lesions of pons, medulla, (Clinical Volume 2, Chapter 10) 
motor commands for conjugate (versional) horizontal movements, (Clinical Volume 2, Chapter 10) 
brainstem control of, (Foundations Volume 1, Chapter 38) 
Horizontal gaze. See Gaze, horizontal
Horizontal strabismus, chemodenervation in, (Clinical Volume 6, Chapter 89) 
Horizontal transposition, of vertical rectus muscles, (Clinical Volume 6, Chapter 97) 
Hormones. See also Endocrine diseases; Glucocorticoids
aqueous formation and, (Foundations Volume 2, Chapter 6) 
steroid. (See Corticosteroids)
Horner tensor tarsi muscle, (Foundations Volume 1, Chapter 5) 
Horner-Trantas’ dots, (Clinical Volume 4, Chapter 2) 
in vernal conjunctivitis, 2–3, (Clinical Volume 4, Chapter 9) 
Horseradish peroxidase (HRP), (Foundations Volume 2, Chapter 40) 
Hoskin anatomic classification of developmental glaucomas, (Clinical Volume 3, Chapter 51) 
Host defenses. See Immune response
House fly Titmus Stereotest, (Clinical Volume 1, Chapter 14) 
HPETE. See Hydroperoxyeicosatetraenoic acid
HPV. See Human papillomavirus
HRP. See Horseradish peroxidase
HSV. See Herpes simplex virus
scleral, after retinal reattachment, (Foundations Volume 3, Chapter 6) 
Toxoplasm gondii and, (Foundations Volume 2, Chapter 82) 
Hudson-Stahli lines, vortex keratopathy and, (Clinical Volume 4, Chapter 17) 
Hughes procedure, in lid reconstruction, (Clinical Volume 5, Chapter 88) (Clinical Volume 6, Chapter 110) 
Human bite wounds, (Clinical Volume 5, Chapter 75) 
Human cytogenetics, (Foundations Volume 2, Chapter 52) 
Human Genome Project, (Foundations Volume 3, Chapter 55) 
Human genome sequence
candidate gene screening and, (Foundations Volume 1, Chapter 19A) 
Human herpesviruses. See Herpesviruses
Human immunodeficiency virus (HIV), (Foundations Volume 2, Chapter 82) (Foundations Volume 2, Chapter 85) See also Acquired immunodeficiency syndrome (AIDS); See also HIV/AIDS
acute retinal necrosis syndrome in, (Clinical Volume 3, Chapter 28) 
adnexal manifestations, (Foundations Volume 2, Chapter 36) 
anterior segment manifestations, (Foundations Volume 2, Chapter 36) 
antiviral therapy
postexposure prophylaxis, (Foundations Volume 2, Chapter 64) 
and conjunctival flora, (Foundations Volume 2, Chapter 41) 
drug-related ocular toxicity in, (Foundations Volume 2, Chapter 36) 
facial nerve palsy in, (Clinical Volume 2, Chapter 8) 
human herpesvirus 6 and, (Foundations Volume 2, Chapter 93) 
natural history, 2, (Foundations Volume 2, Chapter 36) 
neuro-ophthalmic manifestations, (Foundations Volume 2, Chapter 36) 
ocular manifestations, (Foundations Volume 2, Chapter 36 ) 
in developing countries, (Foundations Volume 2, Chapter 36) 
optic neuropathies with, (Clinical Volume 2, Chapter 5) 
orbital manifestations, (Foundations Volume 2, Chapter 36) 
posterior segment manifestations, (Foundations Volume 2, Chapter 36) 
transmission from donor cornea, (Clinical Volume 6, Chapter 26) 
tuberculosis and, (Clinical Volume 4, Chapter 58) 
Human leukocyte antigens. See Histocompatibility antigens
Human T-cell leukemia virus (HTLV), infection, intermediate uveitis in, (Clinical Volume 4, Chapter 43) 
Human T-cell lymphotropic virus type 1, serology, (Foundations Volume 2, Chapter 40) 
Humor, aqueous, (Foundations Volume 2, Chapter 6) 
aqueous formation, factors affecting, (Foundations Volume 2, Chapter 6) 
aqueous formation rate, mathematical derivation of, (Foundations Volume 2, Chapter 6) 
aqueous outflow, (Foundations Volume 2, Chapter 6) 
methods of measurement of, (Foundations Volume 2, Chapter 6) 
blood-aqueous barrier, (Foundations Volume 2, Chapter 6) 
dialysis, ultrafiltration, (Foundations Volume 2, Chapter 6) 
Gibbs-Donnan equilibrium, (Foundations Volume 2, Chapter 6) 
measuring rates of aqueous formation, (Foundations Volume 2, Chapter 6) 
pathways of aqueous flow, (Foundations Volume 2, Chapter 6) 
pharmacologic agent effects on, (Foundations Volume 3, Chapter 25) 
intraocular pressure
non-steady-state alteration, by pharmacologic agents, (Foundations Volume 3, Chapter 25) 
non-steady-state alterations of, (Foundations Volume 3, Chapter 25) 
alpha-adrenergic agonists, (Foundations Volume 3, Chapter 25) 
beta-adrenergic agonists, (Foundations Volume 3, Chapter 25) 
beta-adrenergic antagonists, (Foundations Volume 3, Chapter 25) 
carbonic anhydrase inhibitors, (Foundations Volume 3, Chapter 25) 
cholinergic agents, (Foundations Volume 3, Chapter 25) 
prostaglandin analogues, (Foundations Volume 3, Chapter 25) 
steady-state alterations of, (Foundations Volume 3, Chapter 25) 
active and passive mechanisms of formation, (Foundations Volume 3, Chapter 25) 
alternative model for aqueous humor dynamics, (Foundations Volume 3, Chapter 25) 
aqueous humor formation, (Foundations Volume 3, Chapter 25) 
aqueous humor outflow, (Foundations Volume 3, Chapter 25) 
episcleral venous pressure, (Foundations Volume 3, Chapter 25) 
measurement of rate of aqueous humor formation, (Foundations Volume 3, Chapter 25) 
trabecular meshwork outflow, (Foundations Volume 3, Chapter 25) 
uveoscleral outflow, (Foundations Volume 3, Chapter 25) 
secondary aqueous, (Foundations Volume 2, Chapter 6) 
trabecular pathway, (Foundations Volume 2, Chapter 6) 
uveoscleral pathway, (Foundations Volume 2, Chapter 6) 
Humoral intraocular defenses, (Foundations Volume 2, Chapter 45) 
Humorsol. See Demecarium (Humorsol)
Humphrey Field Analyzer, (Foundations Volume 2, Chapter 109) See also Automated perimetry
background illumination, (Foundations Volume 2, Chapter 109) 
Humphrey perimeter
apostilbs and decibels on, (Clinical Volume 3, Chapter 49) 
central 10 degrees, (Clinical Volume 3, Chapter 49) 
central thresholding programs, (Clinical Volume 3, Chapter 49) 
Humphrey Ultrasound Biomicroscope, 2, (Foundations Volume 2, Chapter 106) 
Humphrey Visual Field Analyzer, (Clinical Volume 2, Chapter 2) 
Huntington disease, (Clinical Volume 2, Chapter 10) 
Huntington disease, eye movements in, (Clinical Volume 2, Chapter 10) 
Hutchinson-Tay central guttate choroiditis, (Clinical Volume 3, Chapter 9) 
Huygens’ theory of light, (Clinical Volume 1, Chapter 31) 
Hyaline bodies. See also Drusen
Hyaline plaques
scleral, ultrasound biomicroscopy, (Foundations Volume 2, Chapter 106) 
senile, of sclera, (Clinical Volume 4, Chapter 23) 
Hyalinosis cutis et mucosae, (Clinical Volume 4, Chapter 15) 
Hyalocytes, vitreous, (Foundations Volume 1, Chapter 16) 
Hyaloidal fibrovascular proliferation, anterior, (Clinical Volume 3, Chapter 54E) (Foundations Volume 3, Chapter 18) 
after diabetic vitrectomy, (Clinical Volume 6, Chapter 57) 
Hyaloid artery, development, (Foundations Volume 1, Chapter 2) (Clinical Volume 3, Chapter 8) 
posterior, traction, macular edema and, vitrectomy in, (Clinical Volume 6, Chapter 57) 
Hyaloid corpuscle. See Mittendorf’s dots
Hyaloid membrane, anterior, posterior zonular attachment to, (Foundations Volume 1, Chapter 14) 
Hyaloidotomy, Nd: YAG, (Clinical Volume 6, Chapter 19) 
Hyaloid tract (retrolental tract)
developmental anomalies, (Foundations Volume 3, Chapter 53) 
Hyaloid vascular system
Hyalosis, asteroid. See Asteroid hyalosis
ultrasonography, (Clinical Volume 3, Chapter 3) 
Hyaluronic acid, in vitreous, (Clinical Volume 6, Chapter 51) 
collagen interaction with, (Clinical Volume 6, Chapter 51) 
Hyaluronidase
aqueous outflow facility, (Clinical Volume 3, Chapter 45) 
with local anesthetics, (Foundations Volume 3, Chapter 35) 
pharmacologic vitreolysis, (Foundations Volume 2, Chapter 11) 
“Hybrid” cysts, (Foundations Volume 3, Chapter 7) 
Hybridization, nucleic acid, (Foundations Volume 2, Chapter 40) 
Hybridization assays, (Clinical Volume 4, Chapter 35) 
Hydantoins, teratogenicity, (Foundations Volume 1, Chapter 39) 
Hydatid disease. See Echinococcosis
Hydralazine, (Foundations Volume 3, Chapter 29) 
effect on ocular blood flow, (Foundations Volume 2, Chapter 5) 
Hydration state of oral medications, bioinequivalence and, (Foundations Volume 3, Chapter 22) 
Hydraulic injection injuries, orbital, (Clinical Volume 2, Chapter 28) 
Hydrocarbons, cataract from, (Clinical Volume 1, Chapter 73) 
Hydrocephalus
internal, chiasmal syndromes in, (Clinical Volume 2, Chapter 6) 
in Maroteaux-Lamy syndrome, (Clinical Volume 2, Chapter 5) 
in mucopolysaccharidoses, (Clinical Volume 2, Chapter 5) 
in optic gliomas, (Clinical Volume 2, Chapter 6) 
Hydrocortisone, ocular toxicity, (Clinical Volume 5, Chapter 37) See Cortisol
Hydrodelineation, in phacoemulsification, (Clinical Volume 6, Chapter 7) 
Hydrodissection, (Clinical Volume 6, Chapter 6) 
Hydrodissection, hydrodelineation and, in phacoemulsification, (Clinical Volume 6, Chapter 7) 
Hydrogel lenses, (Clinical Volume 4, Chapter 11) See also Contact lenses, soft
adjunctive measures, (Clinical Volume 4, Chapter 11) 
benefits, expected, (Clinical Volume 4, Chapter 11) 
clinical applications, (Clinical Volume 4, Chapter 11) 
conjunctivitis and, giant papillary, (Clinical Volume 4, Chapter 11) 
contraindications, (Clinical Volume 4, Chapter 11) 
corneal neovascularization and edema and, (Clinical Volume 4, Chapter 11) 
fitting characteristics, desired, (Clinical Volume 4, Chapter 11) 
fluorescein use and, (Clinical Volume 4, Chapter 11) 
microbial keratitis and, (Clinical Volume 4, Chapter 11) 
porcine collagen, (Clinical Volume 4, Chapter 11) 
preservatives and, (Clinical Volume 4, Chapter 11) 
“taco test, ”, (4) 11: 3
topical antibiotic prophylaxis and, (Clinical Volume 4, Chapter 11) 
topical medication administration and, (Clinical Volume 4, Chapter 11) 
Hydrogen peroxide, in contact lens care, (Foundations Volume 2, Chapter 80) 
peripheral programs, (Clinical Volume 3, Chapter 49) 
short-term fluctuation and, (Clinical Volume 3, Chapter 49) 
threshold-related strategy on, (Clinical Volume 3, Chapter 49) 
Hydromorphone, ocular toxicity, (Clinical Volume 5, Chapter 37) 
Hydroperoxyeicosatetraenoic acid (HPETE), in inflammation, (Foundations Volume 2, Chapter 27) 
Hydrophilic bandage lens, in chemical injuries, (Clinical Volume 4, Chapter 28) 
Hydrophilic lenses. See Contact lenses, soft
Hydroxyamphetamine (Paredrine). See also Amphetamines
in neuroanatomic localization of Horner’s syndrome, (Foundations Volume 2, Chapter 9) 
side effects, in infants and children, (Foundations Volume 3, Chapter 43) 
systemic toxicity, (Clinical Volume 5, Chapter 37) 
in test for oculosympathetic paresis, (Clinical Volume 2, Chapter 15) 
Hydroxyapatite orbital implants
complications, management, (Clinical Volume 5, Chapter 83) 
insertion within Tenon’s fascia, (Clinical Volume 5, Chapter 83) 
posterior uveal melanoma and, enucleation for, (Clinical Volume 6, Chapter 70) 
Hydroxychloroquine, ocular toxicity, (Clinical Volume 3, Chapter 33) (Clinical Volume 5, Chapter 37) 
vortex keratopathy and, (Clinical Volume 4, Chapter 17) 
6-Hydroxydopamine (6-OHDA)
effect on aqueous humor, (Foundations Volume 3, Chapter 29) 
effect on catecholamine systems, (Foundations Volume 3, Chapter 29) 
Hydroxyeicosatetraenoic acid (HETE), in inflammation, (Foundations Volume 2, Chapter 27) 
Hydroxyfluoric acid, ocular injury, (Clinical Volume 4, Chapter 28) 
Hydroxyheptadecatrienoic acid, (Foundations Volume 2, Chapter 27) 
Hydroxypropyl methylcellulose
in ophthalmic solutions, and bioavailability, (Foundations Volume 3, Chapter 22) 
viscoelastic material, (Clinical Volume 6, Chapter 9) 
Hydroxyzine hydrochloride, for atopic dermatitis, (Clinical Volume 5, Chapter 57) 
Hygiene, in infection prevention, (Foundations Volume 2, Chapter 43) 
Hymenolepsis nana, phlyctenular keratoconjunctivitis and, (Clinical Volume 4, Chapter 8) 
Hyoscine. See Scopolamine
Hyperalgesia, primary and secondary, (Foundations Volume 2, Chapter 2) 
Hyperbaric oxygen
for radionecrosis, (Clinical Volume 2, Chapter 6) 
for retinal artery occlusion, central, (Clinical Volume 3, Chapter 14) 
for tissue necrosis, after lid trauma repair, (Clinical Volume 5, Chapter 75) 
Hyperbetalipoproteinemia, (Clinical Volume 4, Chapter 15) 
Hyperbilirubinemia, phototherapy for, (Clinical Volume 5, Chapter 39) 
Hypercalcemia
idiopathic infantile, cornea in, (Clinical Volume 4, Chapter 15) 
Hypercapnia, contact lenses and, (Clinical Volume 4, Chapter 27) 
Hypercholesterolemic xanthomatosis, (Clinical Volume 5, Chapter 41) 
Hypercholesterolemic xanthomatosis, essential, cataract in, (Clinical Volume 5, Chapter 41) 
Hyperchylomicronemia, (Clinical Volume 4, Chapter 15) 
hyperprebetalipoproteinemia and, (Clinical Volume 4, Chapter 15) 
Hypercupremia. See Wilson’s disease
Hyperdeviations, dissociated. See Dissociated vertical deviations
Hyperemesis gravidarum, (Clinical Volume 5, Chapter 32) 
Hyperhomocysteinemia, 5–6, (Clinical Volume 5, Chapter 23) 
Hyperimmunoglobulin E syndrome, (Clinical Volume 4, Chapter 9) 
Hyperkeratosis, epidermolytic, (Clinical Volume 5, Chapter 27) See also Ichthyosis; (Foundations Volume 3, Chapter 7) 
Hyperkeratotic disorders, (Clinical Volume 5, Chapter 27 ) 
Hyperkinetic disorders, (Clinical Volume 2, Chapter 8) 
facial myokymia, (Clinical Volume 2, Chapter 8) 
facial synkinesis, (Clinical Volume 2, Chapter 8) 
gustatory sweating, (Clinical Volume 2, Chapter 8) 
gustatory tearing. (See Crocodile tears)
hemifacial spasm, (Clinical Volume 2, Chapter 8) 
Hyperlipidemia, cornea in, (Clinical Volume 5, Chapter 30) 
Hypermature cataract, (Clinical Volume 1, Chapter 73) 
Hypermetropia, (Foundations Volume 1, Chapter 1) See Hyperopia
Hyperopia, inheritance, (Foundations Volume 3, Chapter 65) 
in accommodative esodeviations, (Clinical Volume 1, Chapter 12) 
after radial keratotomy, (Clinical Volume 6, Chapter 41) 
in anisometropia, (Clinical Volume 1, Chapter 33) 
axial
and image size of object at far point, (Clinical Volume 1, Chapter 33) 
and retinal image size after spectacle correction, (Clinical Volume 1, Chapter 33) 
binocular relationships in, (Clinical Volume 1, Chapter 36) 
chromatic blur in, (Clinical Volume 1, Chapter 33) 
with cystoid macular edema, (Clinical Volume 3, Chapter 19) 
esodeviations in, (Clinical Volume 1, Chapter 36) 
latent, Fresnel lenses in, (Clinical Volume 1, Chapter 52) 
partial versus full correction, (Clinical Volume 1, Chapter 36) 
visual acuity as function of refractive error, (Clinical Volume 1, Chapter 33) 
in vitelliform dystrophy, (Clinical Volume 3, Chapter 9) 
Hyperopic astigmatism, (Clinical Volume 1, Chapter 33) 
Hyperornithinemia, in gyrate atrophy, (Clinical Volume 3, Chapter 25) (Clinical Volume 4, Chapter 66) 
Hyperoxaluria, primary, type I, (Clinical Volume 5, Chapter 31) 
Hyperphoria
vertical vergence amplitude in, (Clinical Volume 1, Chapter 7) 
Hyperpigmentation, of lids, (Foundations Volume 1, Chapter 28) 
Hyperplasia. See also Hamartoma
angiolymphoid, with eosinophilia. (See Kimura’s disease)
lymphoid. (See Lymphoid hyperplasia)
reactive, benign, (Clinical Volume 2, Chapter 39) 
retinal pigment epithelium, (Clinical Volume 3, Chapter 7) 
vitreous, persistent primary, (Clinical Volume 3, Chapter 54E) 
Hyperprebetalipoproteinemia, (Clinical Volume 4, Chapter 15) 
hyperchylomicronemia and, (Clinical Volume 4, Chapter 15) 
Hyperprolactinemia, (Clinical Volume 2, Chapter 6) 
empty sella syndrome and, (Clinical Volume 2, Chapter 6) 
Hypersensitivity. See Allergy and hypersensitivity; Allergy(ies); Immunology
delayed. (See Hypersensitivity, type IV)
in rheumatoid diseases, (Foundations Volume 2, Chapter 33 ) 
skin diseases due to, (Foundations Volume 2, Chapter 29 ) 
Hypertelorism, (Clinical Volume 5, Chapter 29) (Clinical Volume 6, Chapter 110) See also Craniofacial anomalies; (Foundations Volume 1, Chapter 40) 
in Conradi’s syndrome, (Clinical Volume 5, Chapter 29) 
optic disc abnormalities in, (Clinical Volume 2, Chapter 5) 
Hypertension, (Clinical Volume 3, Chapter 13) See also Blood pressure
arterial
systemic, fluorescein angiography, (Foundations Volume 2, Chapter 113C) 
choroidopathy and, (Clinical Volume 3, Chapter 13) 
glaucoma and, primary open-angle, (Clinical Volume 3, Chapter 52) 
intracranial. (See Intracranial pressure increase)
in polyarteritis nodosa, (Clinical Volume 2, Chapter 35) 
pregnancy-induced, (Clinical Volume 5, Chapter 32) 
in retinal artery occlusion, central, (Clinical Volume 3, Chapter 14) 
in retinal vein occlusion
topical phenylephrine effects on, (Foundations Volume 3, Chapter 29) 
Hyperthermia
malignant
maternal
ocular teratogenicity of, (Clinical Volume 5, Chapter 39) 
ocular teratogenicity, (Foundations Volume 1, Chapter 39) 
Hyperthyroidism, (Clinical Volume 5, Chapter 21) See also Graves’ disease
Hypertrophy, retinal pigment epithelium
inferior oblique muscle, (Clinical Volume 1, Chapter 17) 
Hypertropia
in dissociated vertical deviations, (Clinical Volume 1, Chapter 18) 
Hyperventilation, (Clinical Volume 2, Chapter 18) 
Hyperviscosity retinopathy, (Clinical Volume 5, Chapter 23) 
Hypoesthesia, corneal, contact lens-associated, (Clinical Volume 4, Chapter 27) 
Hypofibrinolysis, tests for, (Clinical Volume 5, Chapter 23) 
Hypoglycemia, of childhood, cataract in, (Clinical Volume 5, Chapter 41) 
Hypoglycemia of childhood, (Clinical Volume 5, Chapter 41) 
Hypomelanotic patches, in tuberous sclerosis, (Clinical Volume 5, Chapter 36) 
Hypoparathyroidism, cataract from, (Clinical Volume 1, Chapter 73) 
Hypopigmentation. See Albinism
Hypopyon
cytomegalovirus retinitis and, (Clinical Volume 3, Chapter 28A) 
in phacolytic glaucoma, 2, (Clinical Volume 3, Chapter 54A) 
soft contact lens-induced, (Clinical Volume 4, Chapter 62) 
Hypotension
ocular, contralateral, topical -blockers and, (Foundations Volume 3, Chapter 40) 
Hypotensive agents, in chemical injuries, (Clinical Volume 4, Chapter 28) 
Hypotonia
after trabeculectomy, (Foundations Volume 3, Chapter 6) 
intraocular pressure in, (Foundations Volume 2, Chapter 7) 
Hypotony, (Clinical Volume 3, Chapter 58 ) 
from cyclodialysis, (Clinical Volume 3, Chapter 58) 
intraocular, chorioretinal folds caused by, (Clinical Volume 3, Chapter 36) 
from iridocyclitis, (Clinical Volume 3, Chapter 58) 
from overfiltration, (Clinical Volume 3, Chapter 58) 
postoperative, after glaucoma surgery, (Clinical Volume 6, Chapter 24) 
aqueous misdirection and, (Clinical Volume 6, Chapter 24) 
pupillary block and, (Clinical Volume 6, Chapter 24) 
from retinal detachment, (Clinical Volume 3, Chapter 58) 
from systemic disorders, (Clinical Volume 3, Chapter 58) 
tube shunts and
late complications, (Clinical Volume 6, Chapter 17) 
Hypotropia
in adhesive syndrome, (Clinical Volume 1, Chapter 17) 
third nerve palsy, (Clinical Volume 1, Chapter 19) 
in thyrotoxicosis ophthalmoplegia, (Clinical Volume 1, Chapter 20) 
Hypoxia, gram-negative bacilli and, (Foundations Volume 2, Chapter 52) 
contact lenses and, (Clinical Volume 4, Chapter 27) 
corneal edema due to, (Clinical Volume 4, Chapter 27) 
ocular, chronic. (See also Ocular ischemic syndrome)
in carotid atheromatous disease, (Clinical Volume 2, Chapter 5) 
orbital, signs of, (Clinical Volume 2, Chapter 5) 
Hysteresis, scleral, (Foundations Volume 2, Chapter 4) 
Hysteria
field defects in, (Clinical Volume 2, Chapter 2) 
visual evoked potential, (Foundations Volume 2, Chapter 105) 

 Back to Top

Subject Index I
Iatrogenic immunosuppression, (Clinical Volume 5, Chapter 40) 
IBD. See Inflammatory bowel disease
Ibuprofen
Ibuprofen. See Nonsteroidal anti-inflammatory drugs (NSAIDs)
ICAM-1. See Intercellular adhesion molecule-1 (ICAM-1)
Ice hockey, eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45) 
Iceland type peripapillary chorioretinal degeneration, (Clinical Volume 4, Chapter 66) 
ICG. See Indocyanine green
ICGA. See Angiography, indocyanine green
Identification acuity, (Foundations Volume 2, Chapter 17) 
Idiocy
amaurotic familial, (Clinical Volume 2, Chapter 5) 
Idiopathic infantile hypercalcemia, cornea in, (Clinical Volume 4, Chapter 15) 
Idiopathic midline destructive disease, (Clinical Volume 2, Chapter 35) 
Idiopathic polyneuritis
Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN), (Clinical Volume 3, Chapter 22) 
Idiopathic thrombocytopenic purpura, (Clinical Volume 5, Chapter 23) 
Ifenprodil, and retinal ganglion cells, (Clinical Volume 3, Chapter 57) 
Ig. See Immunoglobulins
IgA. See Immunoglobulin A
IgE. See Immunoglobulin E
IgG. See Immunoglobulin G
IgM. See Immunoglobulin M
Ileitis, regional. See Crohn’s disease
ILL. See Internal limiting lamina
Illiterate E chart, (Clinical Volume 5, Chapter 51) 
Illumination, (Foundations Volume 2, Chapter 15) See also Luminance
in glare testing, (Clinical Volume 1, Chapter 35) 
in indirect ophthalmoscopy, (Clinical Volume 1, Chapter 63) 
levels of, in indirect ophthalmoscopy, (Clinical Volume 1, Chapter 63) 
occupational ophthalmoscopy and, (Clinical Volume 5, Chapter 47) 
ophthalmoscopy and, (Clinical Volume 1, Chapter 63) 
reduced, visual acuity and, (Clinical Volume 2, Chapter 2) 
slit lamp. (See Slit lampfor)
Illusory visual spread, (Foundations Volume 2, Chapter 22) 
Images
digital, ophthalmoscopy and, (Clinical Volume 1, Chapter 63) 
disparity in, bitemporal, (Clinical Volume 1, Chapter 7) 
dissimilar
threshold precluding fusion, (Clinical Volume 1, Chapter 5) 
in indirect ophthalmoscopy, (Clinical Volume 1, Chapter 63) 
jump, from bifocals, (Clinical Volume 1, Chapter 44) 
processing of, in videokeratoscopy, (Clinical Volume 1, Chapter 65) 
Imaging. See Radiology; specific modality
Imbert-Fick principle, 2, (Clinical Volume 3, Chapter 46) 
Imipramine
ocular toxicity of, (Clinical Volume 5, Chapter 37) 
IML. See Internal medullary lamina
Immediate hypersensitivity. See Anaphylaxis
Immune-complex reactions. See also Hypersensitivity, type III
in external tissues, (Foundations Volume 2, Chapter 26) 
in internal tissues, (Foundations Volume 2, Chapter 26) 
Immune deviation, anterior chamber-associated, (Foundations Volume 2, Chapter 28A) (Foundations Volume 2, Chapter 98) 
Immune privilege, ocular, (Clinical Volume 4, Chapter 34) 
Immune response, (Clinical Volume 4, Chapter 2)  (Clinical Volume 4, Chapter 34) See also Allergy and hypersensitivity; Immunology; (Foundations Volume 2, Chapter 25) See also Allergy(ies); Hypersensitivity
antigen-presenting cells in, (Clinical Volume 4, Chapter 2) 
autoimmunity. (See Autoimmunity)
basophils in, (Foundations Volume 2, Chapter 25) 
antibody responses and, (Foundations Volume 2, Chapter 77) 
cell-mediated immunity and, (Foundations Volume 2, Chapter 77) 
histopathology and, (Foundations Volume 2, Chapter 77) 
B lymphocytes in, (Clinical Volume 4, Chapter 2) 
clinical analysis, molecular genetic techniques, (Clinical Volume 4, Chapter 35) 
complement system in, (Foundations Volume 2, Chapter 25) 
in corneal graft rejection, (Foundations Volume 3, Chapter 6) 
dendritic cells in, (Foundations Volume 2, Chapter 25) 
in external tissues
immune-complex mediated, (Foundations Volume 2, Chapter 26) 
in giant papillary conjunctivitis, (Clinical Volume 4, Chapter 9A) 
to gonococcal antigen, (Foundations Volume 2, Chapter 50) 
granulocytes in, (Clinical Volume 4, Chapter 2) 
herpes simplex ocular diseases, (Foundations Volume 2, Chapter 89) 
HLA system in. (See HLA system)
humoral immunity, (Clinical Volume 4, Chapter 2) 
immunoglobulins in, (Foundations Volume 2, Chapter 25) 
in internal tissues
immune-complex mediated, (Foundations Volume 2, Chapter 26) 
killer cells in, (Clinical Volume 4, Chapter 2) 
lymphocyte activation in, (Clinical Volume 4, Chapter 2) 
lymphoid tissues in, (Foundations Volume 2, Chapter 25) 
macrophages in, (Clinical Volume 4, Chapter 2) 
cell-mediated immunity and, (Clinical Volume 4, Chapter 2) 
major histocompatibility complex in, (Foundations Volume 2, Chapter 25) 
to meningococcal antigen, (Foundations Volume 2, Chapter 50) 
mononuclear phagocytes in, (Foundations Volume 2, Chapter 25) 
natural killer cells in, (Clinical Volume 4, Chapter 2) 
neuropathies and, (Clinical Volume 2, Chapter 8) 
physiochemical barriers in, (Foundations Volume 2, Chapter 25) 
in rheumatoid arthritis, (Foundations Volume 2, Chapter 33) 
T-cell receptor complex in, (Foundations Volume 2, Chapter 25) 
third population cells in, (Clinical Volume 4, Chapter 2) 
T lymphocytes in, (Clinical Volume 4, Chapter 2) 
treatment principles. (See Immunomodulation)
to viral infections, (Foundations Volume 2, Chapter 85) (Foundations Volume 2, Chapter 98) 
adhesion molecules and, (Foundations Volume 2, Chapter 98) 
herpes simplex virus, (Foundations Volume 2, Chapter 98) 
in immunologic deficiency syndromes, (Foundations Volume 2, Chapter 98) 
viruses as antigens and, (Foundations Volume 2, Chapter 98) 
virus strategies to avoid host defense mechanisms and, (Foundations Volume 2, Chapter 98) 
Immune rings, corneal, (Clinical Volume 4, Chapter 2) 
in herpes, simplex keratitis, (Clinical Volume 4, Chapter 19) 
Immune therapy. See Immunotherapy
Immunity
cell-mediated, (Foundations Volume 2, Chapter 26) (Foundations Volume 2, Chapter 28) 
atopic dermatitis and, (Foundations Volume 2, Chapter 29) 
chlamydial eye infections and, (Foundations Volume 2, Chapter 77) 
delayed hypersensitivity and, (Foundations Volume 2, Chapter 25) 
in parasitic infections, (Foundations Volume 2, Chapter 79) 
in polymyositis-dermatomyositis, (Foundations Volume 2, Chapter 33) 
in rheumatoid arthritis, (Foundations Volume 2, Chapter 33) 
in varicella-zoster virus infection, (Foundations Volume 2, Chapter 94) 
innate versus acquired, (Foundations Volume 2, Chapter 25) 
mucosal, contact lenses and, (Foundations Volume 2, Chapter 52) 
nonspecific, blood-borne, (Foundations Volume 2, Chapter 28) 
Immunization, (Foundations Volume 2, Chapter 43) 
antibiotic resistance of ocular infections and, (Foundations Volume 2, Chapter 65) 
chlamydial ocular diseases, (Foundations Volume 2, Chapter 77) 
H. influenzae type B, (Clinical Volume 4, Chapter 25) 
herpes simplex ocular diseases, (Foundations Volume 2, Chapter 89) 
influenza, optic neuritis after, (Clinical Volume 2, Chapter 5) 
varicella-zoster virus, (Foundations Volume 2, Chapter 94) 
Immunoassays, solid-phase, (Foundations Volume 2, Chapter 40) 
Immunobiology, normal, (Foundations Volume 2, Chapter 28A) 
Immunodeficiency. See also Acquired immunodeficiency syndrome (AIDS); Human immunodeficiency virus (HIV)
human papillomavirus and, (Foundations Volume 2, Chapter 95) 
viral infections and, (Foundations Volume 2, Chapter 98) 
Immunodeficiency diseases, (Clinical Volume 5, Chapter 40 ) 
acquired. (See HIV/AIDS)
associated with major defects, (Clinical Volume 5, Chapter 40) 
ophthalmic disorders associated with. (See Ophthalmic disorders associated with immunodeficiency diseases)
Immunodetection of ocular infections, (Foundations Volume 2, Chapter 40A) 
Immunofluorescent assay
in bullous pemphigoid, (Clinical Volume 4, Chapter 2) 
in Lyme disease, (Clinical Volume 2, Chapter 5) 
Immunogen. See Antigen(s)
Immunogenetics, uveitis, (Foundations Volume 2, Chapter 28A) 
Immunoglobulin D (IgD), (Foundations Volume 2, Chapter 25) 
Immunoglobulin(s), (Foundations Volume 2, Chapter 25 ) 
in atopic dermatitis, (Foundations Volume 2, Chapter 29) 
in cornea and conjunctiva, (Foundations Volume 2, Chapter 45) 
in external tissues, (Foundations Volume 2, Chapter 26) 
in giant cell arteritis, (Foundations Volume 2, Chapter 33) 
in internal tissues, (Foundations Volume 2, Chapter 26) 
in multiple sclerosis, (Foundations Volume 2, Chapter 35) 
varicella-zoster virus and, (Foundations Volume 2, Chapter 94) 
in Wegener’s granulomatosis, (Foundations Volume 2, Chapter 33) 
Immuno-gold silver staining technique, (Foundations Volume 2, Chapter 88) 
Immunologic detection tests, (Foundations Volume 2, Chapter 40) 
Immunologic diagnosis
agglutination reactions, (Foundations Volume 2, Chapter 40A) 
Bartonella henselae, (Foundations Volume 2, Chapter 40A) 
Borrelia burgdorferi, (Foundations Volume 2, Chapter 40A) 
Haemophilus influenzae, (Foundations Volume 2, Chapter 40A) 
immunodetection of ocular infections, (Foundations Volume 2, Chapter 40A) 
microbial antigens, immunologic detection tests of, (Foundations Volume 2, Chapter 40A) 
Neisseria meningitidis, (Foundations Volume 2, Chapter 40A) 
serologic detection of antibodies, (Foundations Volume 2, Chapter 40A) 
circulating antibodies, (Foundations Volume 2, Chapter 40A) 
serology of ocular infections, (Foundations Volume 2, Chapter 40A) 
solid-phase immunoassays, (Foundations Volume 2, Chapter 40A) 
Staphylococcus aureus, (Foundations Volume 2, Chapter 40A) 
Streptococcus pneumoniae, (Foundations Volume 2, Chapter 40A) 
Treponema pallidum, (Foundations Volume 2, Chapter 40A) 
Immunologic diagnosis of ocular infections, (Foundations Volume 2, Chapter 40A) 
agglutination reactions, (Foundations Volume 2, Chapter 40A) 
Bartonella henselae, (Foundations Volume 2, Chapter 40A) 
Borrelia burgdorferi, (Foundations Volume 2, Chapter 40A) 
Haemophilus influenzae, (Foundations Volume 2, Chapter 40A) 
immunodetection of ocular infections, (Foundations Volume 2, Chapter 40A) 
microbial antigens, immunologic detection tests of, (Foundations Volume 2, Chapter 40A) 
Neisseria meningitidis, (Foundations Volume 2, Chapter 40A) 
serologic detection of antibodies, (Foundations Volume 2, Chapter 40A) 
circulating antibodies, (Foundations Volume 2, Chapter 40A) 
serology of ocular infections, (Foundations Volume 2, Chapter 40A) 
solid-phase immunoassays, (Foundations Volume 2, Chapter 40A) 
Staphylococcus aureus, (Foundations Volume 2, Chapter 40A) 
Streptococcus pneumoniae, (Foundations Volume 2, Chapter 40A) 
Treponema pallidum, (Foundations Volume 2, Chapter 40A) 
Immunologic privilege, ocular, (Foundations Volume 2, Chapter 28A) 
Immunology, (Foundations Volume 2, Chapter 25) (Foundations Volume 2, Chapter 26) See also Allergy(ies); Hypersensitivity; Immune response; See also Immune Response
autoimmunity. (See Autoimmunity)
cell-mediated immunity. (See Immunity, cell-mediated)
components of immune system and, (Foundations Volume 2, Chapter 25) 
in corneal graft rejection, (Clinical Volume 4, Chapter 2) 
of endocrine diseases, (Foundations Volume 2, Chapter 35 ) 
in epidermolysis bullosa, (Clinical Volume 5, Chapter 27) 
of external tissues
immunoglobulin distribution and, (Foundations Volume 2, Chapter 26) 
tear film and lacrimal apparatus and, (Foundations Volume 2, Chapter 26) 
vasculature and, 2, (Foundations Volume 2, Chapter 26) 
graft-versus-host disease and, (Clinical Volume 4, Chapter 2) 
in Graves’ disease, (Clinical Volume 2, Chapter 36) 
herpes simplex keratitis, (Clinical Volume 4, Chapter 2) 
herpes zoster ophthalmicus, (Clinical Volume 4, Chapter 2) 
histocompatibility antigens. (See HLA system)
hypersensitivity and, (Foundations Volume 2, Chapter 25) 
hypersensitivity uveitis and, (Clinical Volume 4, Chapter 34 ) 
of infectious systemic diseases, (Foundations Volume 2, Chapter 32 ) 
innate versus acquired immunity and, (Foundations Volume 2, Chapter 25) 
of internal tissues
immunoglobulin distribution and, (Foundations Volume 2, Chapter 26) 
major histocompatibility complex, (Foundations Volume 2, Chapter 38) 
in Mooren’s ulcer, (Clinical Volume 4, Chapter 2) 
multiple sclerosis and, (Clinical Volume 2, Chapter 5) 
of neurologic diseases, (Foundations Volume 2, Chapter 35 ) 
of ocular infections, (Foundations Volume 2, Chapter 28 ) 
in symphathetic ophthalmia, (Clinical Volume 4, Chapter 51) 
tests, in diagnosis of onchocerciasis, (Clinical Volume 5, Chapter 62) 
in thyroid orbitopathy, (Clinical Volume 2, Chapter 36) 
in toxic epidermal necrolysis, (Clinical Volume 5, Chapter 27) 
Immunomodulation, in atopic dermatitis, (Clinical Volume 5, Chapter 27) 
Immunoperoxidase studies, in viral infections, (Foundations Volume 2, Chapter 88) 
Immunoradiometric assay, TSH, (Clinical Volume 2, Chapter 36) 
Immunosuppression. See also Human immunodeficiancy virus (HIV)
bacterial conjunctivitis and, (Clinical Volume 4, Chapter 5) 
and conjunctival flora, (Foundations Volume 2, Chapter 41) 
for sympathetic ophthalmia, (Clinical Volume 4, Chapter 55) 
in uveitic glaucoma, (Clinical Volume 3, Chapter 54D) 
Immunosuppressive agents, (Clinical Volume 4, Chapter 2) See also specific agent
in cicatrical pemphigoid, (Clinical Volume 4, Chapter 12) 
in pars planitis, (Clinical Volume 4, Chapter 43) 
in Sjorgren’s syndrome, (Clinical Volume 2, Chapter 35) 
in thyroid orbitopathy, (Clinical Volume 2, Chapter 36) 
in thyrotoxicosis, (Clinical Volume 5, Chapter 21) 
in vernal keratoconjunctivitis, (Clinical Volume 4, Chapter 9) 
in Wegener’s granulomatosis, (Clinical Volume 2, Chapter 35) 
Immunosuppressives. See also Immunotherapy
and bacterial flora, (Foundations Volume 2, Chapter 41) 
Immunotoxins, in lymphoma treatment, (Clinical Volume 2, Chapter 39) 
Impairment rating, visual, (Clinical Volume 5, Chapter 51) 
Impetigo contagiosa, of lid
Implantation cysts, (Clinical Volume 2, Chapter 31) 
Implants. See also Intraocular lenses
aqueous drainage, in glaucoma, (Clinical Volume 3, Chapter 52) 
exposure and extrusion of, anophthalmic socket and, (Clinical Volume 5, Chapter 82) 
orbital
in enucleation, (Clinical Volume 5, Chapter 83) See also Enucleation
insertion within Tenon’s fascia, (Clinical Volume 5, Chapter 83) 
nonvascularized
placement within Tenon’s capsule, (Clinical Volume 5, Chapter 83) 
posterior uveal melanoma and, enucleation for, (Clinical Volume 6, Chapter 70) 
in scleral buckling, (Clinical Volume 6, Chapter 59) 
Impression cytology. See Conjunctival impression cytology
Inborn errors of metabolism, (Foundations Volume 3, Chapter 54A) See also Metabolic diseases; specific disease
Inborn errors of metabolism. See Metabolic disorders; specific disorder
Incandescent light, (Foundations Volume 2, Chapter 15) 
Incidence, defined, (Foundations Volume 2, Chapter 43) 
Incisional architecture, (Clinical Volume 6, Chapter 6) 
Incision location, (Clinical Volume 6, Chapter 6) 
Incisions
in astigmatic keratotomy, (Clinical Volume 6, Chapter 42) 
radial, asymmetric, (Clinical Volume 6, Chapter 42) 
radial keratotomy incisions combined with, (Clinical Volume 6, Chapter 42) 
in cataract surgery. (See also Phacoemulsification)
clear corneal
complications of, (Clinical Volume 6, Chapter 3) 
corneoscleral, lamellar, dissection, (Clinical Volume 6, Chapter 3) 
in esotropia surgery, in sixth nerve palsy, (Clinical Volume 6, Chapter 84) 
fornix, in rectus muscle surgery
recession procedure, (Clinical Volume 6, Chapter 83 ) 
resection procedure, (Clinical Volume 6, Chapter 83 ) 
groove (Williamson), (Clinical Volume 6, Chapter 3) 
hinge (Langerman), (Clinical Volume 6, Chapter 3) 
limbal, in rectus muscle surgery
recession procedure, (Clinical Volume 6, Chapter 83 ) 
resection procedure, (Clinical Volume 6, Chapter 83 ) 
in microsurgery
near clear groove (Earnest), (Clinical Volume 6, Chapter 3) 
in parabulbar (sub Tenon’s) anesthesia, (Clinical Volume 6, Chapter 1) 
paracentesis (Fine), (Clinical Volume 6, Chapter 3) 
preferential path for, (Clinical Volume 6, Chapter 3) 
in radial keratotomy, (Clinical Volume 6, Chapter 41) 
inaccurate placement, (Clinical Volume 6, Chapter 41) 
traumatic rupture, (Clinical Volume 6, Chapter 41) 
transsclerally sulcus-sutured PC IOL implantation, (Clinical Volume 6, Chapter 8) 
Inclusion conjunctivitis
Inclusion cyst
epidermal, of eyelid, (Clinical Volume 4, Chapter 3) 
epithelial. (See Cyst(s), epithelial inclusion)
epithelial, conjunctival, (Foundations Volume 3, Chapter 8) 
Inclusion disease. See Cytomegalic inclusion disease
Inclusions, cytoplasmic, in Niemann-Pick disease, (Clinical Volume 3, Chapter 29) 
Incomplete cataracts, (Clinical Volume 1, Chapter 73) 
Incontinentia pigmenti, (Foundations Volume 3, Chapter 59) 
retinoblastoma versus, (Foundations Volume 3, Chapter 21) 
Incontinentia pigmenti, (Clinical Volume 5, Chapter 41) 
Incontinentia pigmenti, X-linked dominant, photocoagulation in, (Clinical Volume 6, Chapter 76) 
Increment threshold spectral sensitivity, in amblyopia, (Clinical Volume 1, Chapter 10) 
Incubators, in microbiology laboratory, (Foundations Volume 2, Chapter 47) 
Incyclovergence, (Clinical Volume 1, Chapter 7) 
Indentation gonioscopy, (Clinical Volume 3, Chapter 44) 
Indentation tonometry, (Foundations Volume 2, Chapter 4) (Foundations Volume 2, Chapter 7) 
combined with applanation tonometry, (Foundations Volume 2, Chapter 7) 
India. See also Third World countries
Indinavir, in postexposure HIV prophylaxis, (Foundations Volume 2, Chapter 64) 
Indirect immunofluorescence, (Foundations Volume 2, Chapter 40) 
in viral infection diagnosis, (Foundations Volume 2, Chapter 88) 
Indirect ophthalmoscopy. See Ophthalmoscopy, indirect
Indirect slit-lamp microscopy, (Clinical Volume 1, Chapter 63) 
Indocyanine green
angiography with, (Clinical Volume 3, Chapter 4A) See also Angiography, indocyanine green
chemical and physical properties, (Clinical Volume 3, Chapter 4A) 
Indocyanine green angiography, (Clinical Volume 5, Chapter 32) 
Indocyanine green (ICG)
chemical properties of, (Foundations Volume 2, Chapter 110) 
pharmacokinetics of, (Foundations Volume 2, Chapter 110) 
Indocyanine green (ICG) angiography, (Foundations Volume 2, Chapter 110 ) 
acute multifocal posterior placoid pigment epitheliopathy, (Foundations Volume 2, Chapter 110A) 
birdshot chorioretinopathy, (Foundations Volume 2, Chapter 110A) 
central serous chorioretinopathy, (Foundations Volume 2, Chapter 110A) 
choroidal hemangioma, (Foundations Volume 2, Chapter 110A) 
choroidal inflammatory disease, (Foundations Volume 2, Chapter 110A) 
choroidal ischemic diseases, (Foundations Volume 2, Chapter 110A) 
choroidal metastases, (Foundations Volume 2, Chapter 110A) 
clinical applications, (Foundations Volume 2, Chapter 110A ) 
digital imaging systems, (Foundations Volume 2, Chapter 110) 
digital subtraction, (Foundations Volume 2, Chapter 110) 
idiopathic polypoidal choroidal vasculopathy, (Foundations Volume 2, Chapter 110A) 
multifocal choroiditis, (Foundations Volume 2, Chapter 110A) 
multiple evanescent white dot syndrome, (Foundations Volume 2, Chapter 110A) 
occult choroidal neovascularization, (Foundations Volume 2, Chapter 110A) 
photographic technique, (Foundations Volume 2, Chapter 110) 
polypoidal choroidal neovascularization, (Foundations Volume 2, Chapter 110A) 
retinal angiomatous proliferation, (Foundations Volume 2, Chapter 110A) 
scanning laser ophthalmoscopy and, (Foundations Volume 2, Chapter 110) 
serpiginous chorioretinopathy, (Foundations Volume 2, Chapter 110A) 
Indoles. See Nonsteroidal anti-inflammatory drugs (NSAIDs)
Indole test, in bacteria identification, (Foundations Volume 2, Chapter 40) 
Indomethacin. See also Nonsteroidal anti-inflammatory drugs (NSAIDs)
in ocular inflammation, (Foundations Volume 2, Chapter 31) 
Indomethacin (Indocin)
toxicity of, ocular, (Clinical Volume 5, Chapter 37) 
in vernal keratoconjunctivitis, (Clinical Volume 4, Chapter 9) 
vortex keratopathy and, (Clinical Volume 4, Chapter 17) 
Induced drug resistance, (Foundations Volume 3, Chapter 23) 
Industrial eye problems, (Clinical Volume 5, Chapter 47) 
Industrial visual problems, (Clinical Volume 5, Chapter 47) 
Industry. See Occupational ophthalmology
Infant. See also Newborn
contrast sensitivity testing, (Foundations Volume 2, Chapter 17) 
corneal abnormalities. (See Cornea)
decreased vision and nystagmus in, ERG, (Foundations Volume 2, Chapter 103) 
premature
vitreous development, (Foundations Volume 1, Chapter 16) 
retinal hemorrhage, (Foundations Volume 3, Chapter 6) 
shaken baby syndrome, (Foundations Volume 3, Chapter 14) 
Infant, blind, 9–16
Infantile glaucoma, (Clinical Volume 3, Chapter 55) 
Infantile metachromatic leukodystrophy, (Foundations Volume 3, Chapter 13) 
Infantile neuronal ceroid-lipofuscinosis, (Foundations Volume 3, Chapter 54B) 
Infantile Nystagmus Syndrome, (Clinical Volume 2, Chapter 11) 
Infants
blind, neuro-ophthalmologic examination, (Clinical Volume 2, Chapter 13) 
cellulitis of face in, (Clinical Volume 4, Chapter 25) 
cycloplegic refraction, (Clinical Volume 1, Chapter 41) 
examination of eye movements, (Clinical Volume 2, Chapter 3) 
intraocular lens in, (Clinical Volume 1, Chapter 68) 
newborn
accommodation in, (Clinical Volume 5, Chapter 39) 
adrenoleukodystrophy in, (Clinical Volume 5, Chapter 30) 
autosomal dominant jaundice syndrome in, (Clinical Volume 5, Chapter 30) 
binocular vision in, (Clinical Volume 5, Chapter 39) 
conjunctivitis in, (Clinical Volume 4, Chapter 6) See also Ophthalmia neonatorum
dacryocystitis in, (Clinical Volume 5, Chapter 79) 
fetal alcohol syndrome in, (Clinical Volume 5, Chapter 39) 
fetal hydantoin syndrome in, (Clinical Volume 5, Chapter 39) 
fetal trimethadione syndrome in, (Clinical Volume 5, Chapter 39) 
form perception in, (Clinical Volume 5, Chapter 39) 
glaucoma in, congenital, cataracts and, (Clinical Volume 3, Chapter 55) See also Glaucoma, developmental
hemangioma, capillary, (Clinical Volume 2, Chapter 37 ) 
hyperbilirubinemia, phototherapy for, (Clinical Volume 5, Chapter 39) 
intraocular pressure in, elevated, ocular effects of, (Clinical Volume 3, Chapter 51) 
low-birth-weight, (Clinical Volume 5, Chapter 39) 
ocular herpes simplex virus infection, (Clinical Volume 4, Chapter 39) 
ophthalmia neonatorum in. (See Ophthalmia neonatorum)
optokinetic nystagmus testing in, (Clinical Volume 5, Chapter 39) 
preferential looking in, (Clinical Volume 5, Chapter 39) 
visual acuity, evaluation and measurement, (Clinical Volume 5, Chapter 39) 
visually evoked cortical potentials in, (Clinical Volume 5, Chapter 39) 
nystagmus in, (Clinical Volume 2, Chapter 3) (Clinical Volume 2, Chapter 11) See also Nystagmus, congenital
premature
retinopathy in. (See Retinopathy of prematurity (retrolental fibroplasia))
saccadic velocity measurements, (Clinical Volume 1, Chapter 21) 
toxoplasmosis in, (Clinical Volume 4, Chapter 46) See also Toxoplasmosis, congenital
vision testing in, (Clinical Volume 5, Chapter 51) 
visual behavioral milestones in, (Clinical Volume 5, Chapter 51) 
Zellweger syndrome in, (Clinical Volume 5, Chapter 31) See also Zellweger (cerebrohepatorenal) syndrome
Infarctions
cerebellar artery, (Clinical Volume 2, Chapter 10) 
choroidal, (2)5: 77, 82
hemorrhagic, retinal, (Foundations Volume 3, Chapter 13) 
medullary, lateral, (Foundations Volume 1, Chapter 38) 
migrainous, migraine with prolonged aura and, (Clinical Volume 2, Chapter 16) 
retinochoroidal, neurosurgery and, (Clinical Volume 2, Chapter 5) 
Infection prophylaxis, (Clinical Volume 6, Chapter 6) 
Infection(s). See also Inflammation; specific infection; specific infections
AIDS-associated, (Foundations Volume 2, Chapter 28) (Foundations Volume 2, Chapter 82) See also Acquired immunodeficiency syndrome (AIDS)
in ataxia-telangiectasia, (Clinical Volume 5, Chapter 36) 
as complication of rectus muscle surgery, (Clinical Volume 6, Chapter 83) 
corneal opacification related to, in developing world, (Clinical Volume 5, Chapter 61) 
cycle of, onchocerciasis and, (Clinical Volume 5, Chapter 62) 
ocular manifestations of acquired muscle disease and, (Clinical Volume 5, Chapter 28) 
opportunistic
atypical mycobacteria, (Clinical Volume 4, Chapter 58) 
in hematologic malignancies, (Clinical Volume 5, Chapter 40) 
postoperative
epikeratophakia and, (Clinical Volume 6, Chapter 103) 
scleral buckling surgery and, (Clinical Volume 6, Chapter 59) 
potential sources, during surgery, (Clinical Volume 4, Chapter 24) 
upper respiratory tract, versus allergic rhinitis, in children, (Clinical Volume 6, Chapter 81) 
Infections, ocular
immunologic diagnosis, (Foundations Volume 2, Chapter 40A) 
agglutination reactions, (Foundations Volume 2, Chapter 40A) 
Bartonella henselae, (Foundations Volume 2, Chapter 40A) 
Borrelia burgdorferi, (Foundations Volume 2, Chapter 40A) 
Haemophilus influenzae, (Foundations Volume 2, Chapter 40A) 
immunodetection of ocular infections, (Foundations Volume 2, Chapter 40A) 
microbial antigens, immunologic detection tests of, (Foundations Volume 2, Chapter 40A) 
Neisseria meningitidis, (Foundations Volume 2, Chapter 40A) 
serologic detection of antibodies, (Foundations Volume 2, Chapter 40A) 
circulating antibodies, (Foundations Volume 2, Chapter 40A) 
serology of ocular infections, (Foundations Volume 2, Chapter 40A) 
solid-phase immunoassays, (Foundations Volume 2, Chapter 40A) 
Staphylococcus aureus, (Foundations Volume 2, Chapter 40A) 
Streptococcus pneumoniae, (Foundations Volume 2, Chapter 40A) 
Treponema pallidum, (Foundations Volume 2, Chapter 40A) 
microbiologic diagnosis, (Foundations Volume 2, Chapter 40) 
antimicrobial susceptibility testing, (Foundations Volume 2, Chapter 40) 
culture isolation, (Foundations Volume 2, Chapter 40) 
bacteria, fungi, and protozoa, (Foundations Volume 2, Chapter 40) 
viruses and chlamydia, (Foundations Volume 2, Chapter 40) 
electron microscopy, (Foundations Volume 2, Chapter 40) 
fluorescence microscopy, (Foundations Volume 2, Chapter 40) 
fluorescein-conjugated stains, (Foundations Volume 2, Chapter 40) 
rhodamine-auramine, (Foundations Volume 2, Chapter 40) 
microbial component detection, (Foundations Volume 2, Chapter 40) 
limulus lysate assay, (Foundations Volume 2, Chapter 40) 
specimen collection, (Foundations Volume 2, Chapter 40) 
Infectious and inflammatory diseases, (Clinical Volume 5, Chapter 33 ) 
allergic. (See Allergy and hypersensitivity)
in children, anesthesia and, (Clinical Volume 6, Chapter 81) 
choroidal atrophy in, (Clinical Volume 4, Chapter 66) 
cornea in
conjunctival flaps and, (Clinical Volume 6, Chapter 33) 
laboratory diagnosis, (Clinical Volume 4, Chapter 1) 
orbital, (2)34: 10; (2) 40: 6. See also Orbit
polymerase chain reaction in, (Clinical Volume 4, Chapter 1) 
in renal transplant patients, (Clinical Volume 5, Chapter 31) 
thyroid eye disease, (Clinical Volume 2, Chapter 34) 
Infectious disease, ocular, molecular diagnosis, (Foundations Volume 2, Chapter 40B) 
polymerase chain reaction, (Foundations Volume 2, Chapter 40B) 
anterior segment and external disease, (Foundations Volume 2, Chapter 40B) 
application to clinical problems, (Foundations Volume 2, Chapter 40B) 
delayed-onset postoperative endophthalmitis, (Foundations Volume 2, Chapter 40B) 
ocular toxoplasmosis, (Foundations Volume 2, Chapter 40B) 
variants of, (Foundations Volume 2, Chapter 40B) 
multiplex polymerase chain reaction, (Foundations Volume 2, Chapter 40B) 
nested polymerase chain reaction, (Foundations Volume 2, Chapter 40B) 
real-time quantitative polymerase chain reaction, (Foundations Volume 2, Chapter 40B) 
reverse transcription-polymerase chain reaction, (Foundations Volume 2, Chapter 40B) 
universal primer polymerase chain reaction, (Foundations Volume 2, Chapter 40B) 
traditional detection techniques, polymerase chain reaction, compared, (Foundations Volume 2, Chapter 40B) 
Whipple’s disease, (Foundations Volume 2, Chapter 40B) 
Infectious endophthalmitis, pathogenesis of, (Foundations Volume 2, Chapter 48) 
Infectious endophythalmitis, (Clinical Volume 4, Chapter 24) 
acute postoperative endophthalmitis, (Clinical Volume 4, Chapter 24) 
acute postoperative infection, (Clinical Volume 4, Chapter 24) 
antimicrobial therapy, (Clinical Volume 4, Chapter 24) 
choice of antimicrobial agent, (Clinical Volume 4, Chapter 24) 
intraocular injections, (Clinical Volume 4, Chapter 24) 
subconjunctival injections, (Clinical Volume 4, Chapter 24) 
systemic antimicrobials, (Clinical Volume 4, Chapter 24) 
topical antimicrobials, (Clinical Volume 4, Chapter 24) 
clinical presentation, (Clinical Volume 4, Chapter 24) 
coagulase-negative staphylococci, (Clinical Volume 4, Chapter 24) 
delayed-onset postoperative endophthalmitis, (Clinical Volume 4, Chapter 24) 
delayed-onset postoperative infection, (Clinical Volume 4, Chapter 24) 
management strategies, (Clinical Volume 4, Chapter 24) 
organism, outcome by, (Clinical Volume 4, Chapter 24) 
propionibacterium acnes, (Clinical Volume 4, Chapter 24) 
staphylococcus aureus, (Clinical Volume 4, Chapter 24) 
Infectious mononucleosis, (Clinical Volume 2, Chapter 8) 
Parinaud’s oculoglandular conjunctivitis and, (Clinical Volume 4, Chapter 4) 
Infectious retinitis, (Clinical Volume 4, Chapter 45 ) 
acute retinal necrosis syndrome, (Clinical Volume 4, Chapter 45) 
cytomegalovirus retinitis, (Clinical Volume 4, Chapter 45) 
diagnostic aspiration, (Clinical Volume 4, Chapter 45) 
endoretinal biopsy, (Clinical Volume 4, Chapter 45) 
Epstein-Barr virus, (Clinical Volume 4, Chapter 45) 
herpes simplex virus retinitis, (Clinical Volume 4, Chapter 45) 
in immunosuppressed patients, (Clinical Volume 4, Chapter 45) 
intravenous cidofovir in, (Clinical Volume 3, Chapter 28A) 
intravitreal fomivirsen in, (Clinical Volume 3, Chapter 28A) 
intravitreal foscarnet in, (Clinical Volume 3, Chapter 28A) 
intravitreal ganciclovir in, (Clinical Volume 3, Chapter 28A) 
local ocular therapy for, (Clinical Volume 3, Chapter 28A) 
oral ganciclovir for, (Clinical Volume 3, Chapter 28A) 
pars plana vitrectomy, (Clinical Volume 4, Chapter 45) 
retinal detachment repair, (Clinical Volume 4, Chapter 45) 
Rift Valley fever retinitis, (Clinical Volume 4, Chapter 45) 
subacute sclerosing panencephalitis, (Clinical Volume 4, Chapter 45) 
surgical approaches to, (Clinical Volume 4, Chapter 45) 
transscleral biopsy, (Clinical Volume 4, Chapter 45) 
Infectious retinopathies, (Clinical Volume 5, Chapter 40) 
Infective endocarditis. See Endocarditis, infective
Infective endocarditis, ocular abnormalities, (Clinical Volume 5, Chapter 22) 
Infectivity, in ophthalmic epidemiology, (Foundations Volume 2, Chapter 43) 
Inferior ligament of Schwalbe, (Clinical Volume 2, Chapter 40) See also Schwalbe’s line
Inferior oblique muscle, (Foundations Volume 1, Chapter 1 Inferior oblique muscle.) See Oblique muscles, inferior
Inferior olive, ocular motility and, (Foundations Volume 2, Chapter 23) 
Inferior orbital fissure, (Foundations Volume 1, Chapter 32) 
Inferior orbitotomy, (Clinical Volume 5, Chapter 86) See also Orbitotomy
Inferior tarsal muscle, (Foundations Volume 1, Chapter 5) 
Infiltrates
ciliary body and choroid, (Clinical Volume 4, Chapter 52) 
corneal
contact lens-associated, (Clinical Volume 4, Chapter 27) 
in herpes simplex necrotizing stromal keratitis, (Clinical Volume 4, Chapter 19) 
focal, in cytomegalovirus retinitis, (Clinical Volume 3, Chapter 28A) 
subepithelial, in corneal graft rejection, (Clinical Volume 4, Chapter 2) 
Infiltrative ophthalmopathy. See Thyroid disorders
Infinite conjugates, (Clinical Volume 1, Chapter 30) 
Inflammation, (Foundations Volume 3, Chapter 1) 
arachidonic acid metabolites and, (Foundations Volume 2, Chapter 27) 
choroidal
fluorescein angiography, (Foundations Volume 2, Chapter 113E ) 
chronic, granulomatous, (Foundations Volume 3, Chapter 1) 
complement system and, (Foundations Volume 2, Chapter 27) 
corticosteroids and. (See Corticosteroids)
fluorescein angiography, (Foundations Volume 2, Chapter 113E ) 
immunotherapy for. (See Immunotherapy)
of lacrimal drainage system, (Foundations Volume 3, Chapter 7) 
mollicutes causing, (Foundations Volume 2, Chapter 59) 
nongranulomatous, (Foundations Volume 3, Chapter 3) See also specific iinflammatory conditions; specific inflammatory conditions
cellular components, (Foundations Volume 3, Chapter 3) 
immune privilege in ocular environment and, (Foundations Volume 3, Chapter 3) 
soluble components of immune system and, (Foundations Volume 3, Chapter 3) 
platelet-activating factor and, (Foundations Volume 2, Chapter 27) 
postoperative
corticosteroids for, (Foundations Volume 3, Chapter 31) 
Inflammation. See also specific location; specific type
cataract associated with, (Clinical Volume 1, Chapter 73) 
lacrimal gland, (Clinical Volume 2, Chapter 40) 
differential diagnosis, (Clinical Volume 2, Chapter 35) 
malignant-like glaucoma in, (Clinical Volume 3, Chapter 53) 
persistent, after cataract surgery, (Clinical Volume 3, Chapter 54G) 
scleral and episcleral, (Clinical Volume 4, Chapter 23) 
Inflammatory bowel disease, (Clinical Volume 5, Chapter 30) 
anterior uveitis and, (Clinical Volume 3, Chapter 54D) 
clinical features, (Clinical Volume 5, Chapter 26) 
Crohn’s disease, (Clinical Volume 5, Chapter 30) 
genetic susceptibility to, (Clinical Volume 5, Chapter 30) 
ulcerative colitis, (Clinical Volume 5, Chapter 30) 
Inflammatory bowel disease (IBD), (Foundations Volume 2, Chapter 34) 
Inflammatory cells, (Foundations Volume 3, Chapter 3) 
Inflammatory choroiditis. See Choroiditis
Inflammatory disease. See Infectious and inflammatory diseases; specific disease
Inflammatory dry eye, (Foundations Volume 2, Chapter 3) 
Inflammatory membrane, in uveitis, (Clinical Volume 4, Chapter 64) 
Inflammatory membranes, (Foundations Volume 3, Chapter 8) 
Inflammatory myopathies, (Clinical Volume 5, Chapter 28) 
Inflammatory optic neuropathies, (Clinical Volume 2, Chapter 5 ) 
Inflammatory rebound phenomenon, corticosteroids and, (Clinical Volume 4, Chapter 19) 
Influenza, vaccination, optic neuritis after, (Clinical Volume 2, Chapter 5) 
Informed consent. See Legal issues, patient informed consent
Infranuclear disorders of eye movement, (Clinical Volume 2, Chapter 12) See also Movements of eye
Infraorbital fissure, (Clinical Volume 2, Chapter 21) 
Infraorbital foramen, (Foundations Volume 1, Chapter 32) 
Infrared oculography, saccadic velocity measurements, (Clinical Volume 1, Chapter 21) 
Infrared radiation, damage from, (Foundations Volume 3, Chapter 6) 
Infratrochlear nerve, (Foundations Volume 1, Chapter 30) 
INH. See Isoniazid
Inheritance, (Foundations Volume 3, Chapter 51) See also Chromosomal abnormalities; Chromosome; Genetics
of chromosomal abnormalities, (Foundations Volume 3, Chapter 51) 
of corneal dystrophies, (Foundations Volume 3, Chapter 63 ) 
current knowledge of, (Foundations Volume 3, Chapter 51) 
genetic transmission, (Foundations Volume 3, Chapter 51) 
ophthalmic family history and, (Foundations Volume 3, Chapter 51) 
Injection
Injections
periocular, pharmacokinetics of, (Foundations Volume 3, Chapter 23) 
Injury. See also specific type
systemic, ocular effects of, (Foundations Volume 3, Chapter 6) 
In-line roller hockey, eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45) 
Inner plexiform layer (IPL)
Innervation. See Nerve(s)
and accommodation response, (Clinical Volume 1, Chapter 7) 
congenital anomalies, (Clinical Volume 2, Chapter 13 ) 
equivalent, Hering’s law of, (Clinical Volume 2, Chapter 3) 
of lacrimal gland, (Clinical Volume 2, Chapter 40) 
optic nerve anatomy, (Clinical Volume 2, Chapter 4) 
retinotopic organization of visual fibers and, (Clinical Volume 2, Chapter 4) 
sensory nerves of globe, (Clinical Volume 2, Chapter 3) 
Inorganic mercurial salts, for lice infestation, (Foundations Volume 2, Chapter 66) 
Instruments, surgical, (Clinical Volume 6, Chapter 3) (Clinical Volume 6, Chapter 3 ) 
for corneal incisions, (Clinical Volume 5, Chapter 4 ) 
for keratomileusis, (Clinical Volume 6, Chapter 46) 
for orbital surgery, (Clinical Volume 5, Chapter 86) 
phacoemulsification equipment and fluids, (Clinical Volume 6, Chapter 6) 
Insulin
for diabetes mellitus, (Foundations Volume 2, Chapter 35) 
Insulin-like growth factor(s)
Integrins
Intensity of light stimulus, (Clinical Volume 1, Chapter 5) 
Intercellular adhesion molecule-1 (ICAM-1), in herpes simplex keratitis, (Clinical Volume 4, Chapter 2) 
Intercellular spaces, (Foundations Volume 1, Chapter 19) 
Intereye comparisons, in field defect identifications, (Clinical Volume 3, Chapter 49) 
Interface cysts, epikeratophakia and, (Clinical Volume 6, Chapter 103) 
Interference fringes, in measuring visual acuity, (Clinical Volume 1, Chapter 66) See also Laser(s)
Interference visual acuity test, (Clinical Volume 1, Chapter 66) See also Laser(s)
Interferometry, laser, (Clinical Volume 1, Chapter 31) 
Intergroup Rhabdomyosarcoma Study Group, (Clinical Volume 2, Chapter 27) 
Interhemispheric connections, (Foundations Volume 1, Chapter 34) 
visual association areas and, (Clinical Volume 2, Chapter 4) 
Interhemispheric visual-verbal disconnection syndrome, (Foundations Volume 2, Chapter 22) 
Interleukins, (Clinical Volume 4, Chapter 34) See also Lymphokines
IL-2, antibody against, for ocular inflammation, (Foundations Volume 2, Chapter 31) 
Internal carotid artery, (Foundations Volume 1, Chapter 32) 
Internal limiting lamina (ILL), retinal, (Foundations Volume 1, Chapter 16) (Foundations Volume 1, Chapter 19) 
posterior vitreous detachment and, (Foundations Volume 1, Chapter 16) 
Internal limiting membrane, (Clinical Volume 4, Chapter 31) (Clinical Volume 6, Chapter 56) 
contraction. (See Epiretinal membranes)
peeling, in macular hole surgery, (Clinical Volume 6, Chapter 56) 
Internal medullary lamina (IML), eye movements and, (Foundations Volume 1, Chapter 18) 
International Headache Society, headache classification, (Clinical Volume 2, Chapter 16) 
Interneural connections, retinal. See Synapse(s)
Interocular suppression, (Foundations Volume 2, Chapter 24) 
Interphotoreceptor retinoid binding protein, (Foundations Volume 1, Chapter 21) 
Interphotoreceptor retinoid-binding protein, (Clinical Volume 3, Chapter 1) 
Interstitial keratitis, (Clinical Volume 3, Chapter 55) 
Interstitial nucleus of Cajal, (Foundations Volume 1, Chapter 38) (Clinical Volume 2, Chapter 10) 
eye movements and, (Foundations Volume 1, Chapter 38) (Foundations Volume 2, Chapter 23 ) 
cortex at temporal and occipital lobe junction and, (Foundations Volume 2, Chapter 23) 
dorsomedial prefrontal cortex and, (Foundations Volume 2, Chapter 23) 
frontal eye fields and, (Foundations Volume 2, Chapter 23) 
inferior parietal cortex and, (Foundations Volume 2, Chapter 23) 
nucleus of optic tract and dorsal terminal nucleus and, (Foundations Volume 2, Chapter 23) 
occipital cortex and, (Foundations Volume 2, Chapter 23) 
vestibular premotor signals and, (Foundations Volume 2, Chapter 23) 
Interstitial retinal binding protein, (Foundations Volume 1, Chapter 19) 
Interstitium of ciliary muscle and uveoscleral outflow, (Clinical Volume 3, Chapter 43) 
Interval of Sturm, (Clinical Volume 1, Chapter 36) 
Intracellular effects, cholinergic receptors and, (Foundations Volume 3, Chapter 26) 
Intracellular enveloped virus, (Foundations Volume 2, Chapter 97) 
Intracellular mature virus, (Foundations Volume 2, Chapter 97) 
Intracellular recordings, of electrical signals from retina, (Foundations Volume 2, Chapter 13) 
Intracranial aneurysms, arteriovenous malformations, (Clinical Volume 5, Chapter 32) 
Intracranial disorders in pregnancy, (Clinical Volume 5, Chapter 32) 
amniotic fluid or air embolism, (Clinical Volume 5, Chapter 32) 
benign intracranial hypertension, (Clinical Volume 5, Chapter 32) 
carotid-cavernous fistulae, (Clinical Volume 5, Chapter 32) 
cerebral venous, sinus thrombosis, (Clinical Volume 5, Chapter 32) 
intracranial aneurysms, arteriovenous malformations, (Clinical Volume 5, Chapter 32) 
intracranial meningioma, (Clinical Volume 5, Chapter 32) 
lymphocytic hypophysitis, (Clinical Volume 5, Chapter 32) 
metastatic choriocarcinoma, (Clinical Volume 5, Chapter 32) 
pituitary adenoma, (Clinical Volume 5, Chapter 32) 
Intracranial meningioma, (Clinical Volume 5, Chapter 32) 
Intracranial optic nerve and chiasm, (Foundations Volume 2, Chapter 21) 
Intracranial pressure increase
in aneurysm ruptures, (Clinical Volume 2, Chapter 17) 
clinical features, (Clinical Volume 2, Chapter 5) 
papilledema and, (Clinical Volume 2, Chapter 5) 
retinal venous pulsation and, (Clinical Volume 2, Chapter 5) 
Intracranial structures, imaging of, (Foundations Volume 1, Chapter 35) 
Intraepithelial neoplasia
benign, hereditary, (Foundations Volume 3, Chapter 8) 
Intraocular events, depolarizing nicotinic antagonists and, (Foundations Volume 3, Chapter 26) 
Intraocular fibrin syndrome, after diabetic vitrectomy, (Clinical Volume 6, Chapter 57) 
Intraocular lens. See also Keratoprosthesis
accommodation and, (Clinical Volume 1, Chapter 68) 
anterior chamber-type lenses
insertion, in children, (Clinical Volume 6, Chapter 101) 
in aphakia, (Clinical Volume 1, Chapter 68) (Clinical Volume 6, Chapter 8)  (Clinical Volume 6, Chapter 8) See also Aphakia, secondary IOL implantation in, secondary IOL implantation. See also Aphakia
contrast sensitivity with, (Clinical Volume 1, Chapter 35) 
custom, wavefront technology, (Clinical Volume 1, Chapter 70) 
damage, in Nd: YAG laser posterior capsulotomy, (Clinical Volume 6, Chapter 10) 
design
optic factors in, (Clinical Volume 1, Chapter 68) 
diffractive bifocal, (Clinical Volume 1, Chapter 68A) 
dislocated
contrast sensitivity and, (Clinical Volume 1, Chapter 35) 
perfluorocarbon liquids and, (Clinical Volume 6, Chapter 54) 
FDA status, and use in children, (Clinical Volume 6, Chapter 101) 
fixation
optic importance, (Clinical Volume 1, Chapter 68) 
gram-negative bacilli and, (Foundations Volume 2, Chapter 52) 
historical perspective on, (Clinical Volume 1, Chapter 68) 
image magnification, (Clinical Volume 1, Chapter 68) 
implantation
after traumatic lens injury, (Clinical Volume 6, Chapter 39) 
anterior chamber lenses, in children, (Clinical Volume 6, Chapter 101) 
complications
in pupil and iris, (Clinical Volume 3, Chapter 54G) 
keratophakia and, (Clinical Volume 1, Chapter 64) 
optical results, (Clinical Volume 1, Chapter 68) 
with additional spectacle correction, (Clinical Volume 1, Chapter 68) 
in binocular patient, (Clinical Volume 1, Chapter 68) 
IOL-spectacle combinations, (Clinical Volume 1, Chapter 68) 
macular degeneration and aphakic correction, (Clinical Volume 1, Chapter 68) 
in monocular patient, (Clinical Volume 1, Chapter 68) 
penetrating keratoplasty and, (Clinical Volume 6, Chapter 26) 
posterior chamber
primary, in children, (Clinical Volume 6, Chapter 101) 
secondary, (Clinical Volume 6, Chapter 8) See also Aphakia, secondary IOL implantation
Kelman multiflex-style, (Clinical Volume 6, Chapter 8) 
lens fragment dislocation and, light from operating microscope and, (Clinical Volume 1, Chapter 68) 
multifocal. (See Multifocal intraocular lenses)
contrast sensitivity and, (Clinical Volume 1, Chapter 35) 
myopia correction and, (Clinical Volume 1, Chapter 42) 
noninfectious postoperative uveitis and, (Clinical Volume 4, Chapter 55) 
ocular growth and, in children, (Clinical Volume 6, Chapter 101) 
optic quality of, (Clinical Volume 1, Chapter 68) 
in pediatric patient, (Clinical Volume 6, Chapter 100) 
posterior chamber lenses
epikeratoplasty as alternative to, (Clinical Volume 6, Chapter 45) 
transsclerally fixated, (Clinical Volume 6, Chapter 8) 
power calculation, (Clinical Volume 1, Chapter 68 ) 
accuracy, factors affecting, (Clinical Volume 1, Chapter 68) 
anterior chamber depth and, (Clinical Volume 1, Chapter 68) 
axial length of eye and, (Clinical Volume 1, Chapter 68) 
corneal curvature and, (Clinical Volume 1, Chapter 68) 
regression analysis IOL formula for, (Clinical Volume 1, Chapter 68) 
second- and third-generation formulas, (Clinical Volume 1, Chapter 68) 
preparation of, for lamellar refractive keratoplasty, (Clinical Volume 1, Chapter 64) 
refractive bifocal, (Clinical Volume 1, Chapter 68A) 
refractive multifocal, (Clinical Volume 1, Chapter 68A) 
with spectacle correction, (Clinical Volume 1, Chapter 68) 
transmission characteristics, (Clinical Volume 1, Chapter 68) 
ultrasound biomicroscopy, (Foundations Volume 2, Chapter 106) 
Intraocular lenses, (Clinical Volume 6, Chapter 11) 
acrylic glistening, (Clinical Volume 6, Chapter 11) 
anterior chamber lenses, pupil-supported lenses, (Clinical Volume 6, Chapter 11) 
cataract surgery, (Clinical Volume 6, Chapter 11) 
cystoid macular edema, (Clinical Volume 6, Chapter 11) 
endothelial cell damage, (Clinical Volume 6, Chapter 11) 
inflammation-mediated complications, (Clinical Volume 6, Chapter 11) 
intraocular lens model selection error, (Clinical Volume 6, Chapter 11) 
lens location problems, (Clinical Volume 6, Chapter 11) 
long-term endothelial cell loss, (Clinical Volume 6, Chapter 11) 
material chemistry, (Clinical Volume 6, Chapter 11) 
acrylics, (Clinical Volume 6, Chapter 11) 
flexible hydrophilic acrylic polymers, (Clinical Volume 6, Chapter 11) 
flexible hydrophobic acrylic polymers, (Clinical Volume 6, Chapter 11) 
haptic materials, (Clinical Volume 6, Chapter 11) 
material summary, (Clinical Volume 6, Chapter 11) 
methods of assessment, (Clinical Volume 6, Chapter 11) 
optic calcification, (Clinical Volume 6, Chapter 11) 
optic precipitates, (Clinical Volume 6, Chapter 11) 
phakic intraocular lenses, (Clinical Volume 6, Chapter 11) 
angle-fixated phakic intraocular lenses, (Clinical Volume 6, Chapter 11) 
Alcon Anterior Chamber Phakic Intraocular Lens, (Clinical Volume 6, Chapter 11) 
iris-fixated phakic intraocular lenses, (Clinical Volume 6, Chapter 11) 
Artisan/Verisyse, (Clinical Volume 6, Chapter 11) 
Food and Drug Administration clinical study, (Clinical Volume 6, Chapter 11) 
posterior chamber phakic intraocular lenses, (Clinical Volume 6, Chapter 11) 
Medennium Phakic refractive lens, (Clinical Volume 6, Chapter 11) 
sizing and general, (Clinical Volume 6, Chapter 11) 
posterior capsule opacification, (Clinical Volume 6, Chapter 11) 
posterior chamber lenses, (Clinical Volume 6, Chapter 11) 
pseudophakic dysphotopsia, (Clinical Volume 6, Chapter 11) 
pseudophakic intraocular lens, (Clinical Volume 6, Chapter 11) 
adjustable-power pseudophakic intraocular lenses, (Clinical Volume 6, Chapter 11) 
Light-Adjustable lens, (Clinical Volume 6, Chapter 11) 
aniridia intraocular lenses, (Clinical Volume 6, Chapter 11) 
aspheric intraocular lenses, (Clinical Volume 6, Chapter 11) 
AcrySof Higher Order Aberration WF Series, (Clinical Volume 6, Chapter 11) 
Sofflex Advanced Optics, (Clinical Volume 6, Chapter 11) 
implantable miniature telescope, (Clinical Volume 6, Chapter 11) 
light-normalizing intraocular lenses, (Clinical Volume 6, Chapter 11) 
Akkommodative ICU, (Clinical Volume 6, Chapter 11) 
BioComFold Intraocular Lens, (Clinical Volume 6, Chapter 11) 
low/high diopter intraocular lenses, (Clinical Volume 6, Chapter 11) 
pseudoaccommodative intraocular lenses, (Clinical Volume 6, Chapter 11) 
pseudophakic intraocular lenses for very small incisions, (Clinical Volume 6, Chapter 11) 
UltraChoice Thin Lens, (Clinical Volume 6, Chapter 11) 
pseudophakic multifocal intraocular lenses, (Clinical Volume 6, Chapter 11) 
Array Multizonal Refractive intraocular lens, (Clinical Volume 6, Chapter 11) 
optical multifocal intraocular lenses, (Clinical Volume 6, Chapter 11) 
Toric intraocular lenses, (Clinical Volume 6, Chapter 11) 
AcrySof Toric intraocular lens, (Clinical Volume 6, Chapter 11) 
Artisan Toric Intraocular Lens, (Clinical Volume 6, Chapter 11) 
C-flex Toric Intraocular Lens, (Clinical Volume 6, Chapter 11) 
STAAR Toric lenses, (Clinical Volume 6, Chapter 11) 
silicone optic discoloration, (Clinical Volume 6, Chapter 11) 
"Snowflake" alteration of polymethylmethacrylate intraocular lens optic, (Clinical Volume 6, Chapter 11) 
Intraocular lens implantation, (Clinical Volume 6, Chapter 6) 
implantation techniques, (Clinical Volume 6, Chapter 6) 
foldable intraocular lenses, (Clinical Volume 6, Chapter 6) 
rigid posterior chamber intraocular lenses, (Clinical Volume 6, Chapter 6) 
Intraocular lens model selection error, (Clinical Volume 6, Chapter 11) 
Intraocular lens-related inflammations and localized endophthalmitis, (Clinical Volume 4, Chapter 41) 
Intraocular masquerade syndromes. See Masquerade syndromes
Intraocular microfilariae, onchocerciasis and, (Clinical Volume 5, Chapter 62) 
Intraocular pressure
non-steady-state alteration, by pharmacologic agents, (Foundations Volume 3, Chapter 25) 
non-steady-state alterations of, (Foundations Volume 3, Chapter 25) 
alpha-adrenergic agonists, (Foundations Volume 3, Chapter 25) 
beta-adrenergic agonists, (Foundations Volume 3, Chapter 25) 
beta-adrenergic antagonists, (Foundations Volume 3, Chapter 25) 
carbonic anhydrase inhibitors, (Foundations Volume 3, Chapter 25) 
cholinergic agents, (Foundations Volume 3, Chapter 25) 
prostaglandin analogues, (Foundations Volume 3, Chapter 25) 
steady-state alterations of, (Foundations Volume 3, Chapter 25) 
active, passive mechanisms of formation, (Foundations Volume 3, Chapter 25) 
alternative model for aqueous humor dynamics, (Foundations Volume 3, Chapter 25) 
aqueous humor formation, (Foundations Volume 3, Chapter 25) 
aqueous humor outflow, (Foundations Volume 3, Chapter 25) 
episcleral venous pressure, (Foundations Volume 3, Chapter 25) 
measurement of rate of aqueous humor formation, (Foundations Volume 3, Chapter 25) 
trabecular meshwork outflow, (Foundations Volume 3, Chapter 25) 
uveoscleral outflow, (Foundations Volume 3, Chapter 25) 
Intraocular pressure in pregnancy, (Clinical Volume 5, Chapter 32) 
Intraocular pressure (IOP), (Foundations Volume 2, Chapter 7) See also Glaucoma; See also Pressure
after cataract surgery, in glaucoma patient, (Clinical Volume 3, Chapter 54G ) 
after orbital surgery, (Clinical Volume 2, Chapter 14) 
after penetrating keratoplasty, (Clinical Volume 3, Chapter 54F) 
after vitrectomy, (Clinical Volume 6, Chapter 56) 
after vitreous surgery, for proliferative vitreoretinopathy, (Clinical Volume 6, Chapter 58) 
alpha-adrenergic drug effects on, (Foundations Volume 3, Chapter 29) 
aqueous formation and, (Foundations Volume 2, Chapter 6) 
baseline, glaucoma treatment and, (Clinical Volume 3, Chapter 56) 
blunt trauma and, (Clinical Volume 3, Chapter 31) 
cataract surgery in pediatric patient and, (Clinical Volume 6, Chapter 100) 
in chemical injuries, (Clinical Volume 4, Chapter 28) 
chronic elevated, as glaucoma model, (Clinical Volume 3, Chapter 57) 
circadian variation, (Clinical Volume 3, Chapter 46) 
corticosteroids and, (Foundations Volume 3, Chapter 31 ) 
cycloplegic drugs affecting, (Clinical Volume 1, Chapter 41) 
distribution throughout eye, (Foundations Volume 2, Chapter 7) 
episcleral venous pressure and, (Foundations Volume 2, Chapter 7) 
in glaucomatocyclitic crisis, (Clinical Volume 3, Chapter 54D) 
increased
hyperosmotic agents for, (Foundations Volume 3, Chapter 28 ) 
from local anesthetics, (Foundations Volume 3, Chapter 35) 
tissue changes caused by, (Foundations Volume 3, Chapter 19) 
increase in
closed angle mechanisms, (Clinical Volume 3, Chapter 54D) 
in herpes zoster ophthalmicus, (Clinical Volume 3, Chapter 54D) 
HLA-B27-positive anterior uveitis and, (Clinical Volume 3, Chapter 54D) 
in Nd:YAG laser posterior capsulotomy, (Clinical Volume 6, Chapter 10) 
open angle mechanisms, (Clinical Volume 3, Chapter 54D) 
photocoagulation and, (Clinical Volume 6, Chapter 76) 
retinal damage caused by, (Clinical Volume 3, Chapter 57) 
vascular risk factors and, (Clinical Volume 3, Chapter 57) 
muscarinic agonists and
muscarinic antagonists and, (Foundations Volume 3, Chapter 26) 
non-steady-state alterations
orbital disease and, (Clinical Volume 2, Chapter 22) 
outflow facility measurement and, (Foundations Volume 2, Chapter 7) 
before penetrating keratoplasty, (Clinical Volume 6, Chapter 26) 
plasma osmolality and, (Foundations Volume 2, Chapter 7) 
postoperative, vitreous substitutes and, (Clinical Volume 6, Chapter 56) 
quantitative relationships, (Foundations Volume 2, Chapter 7) 
reduction of
in glaucoma, developmental, (Clinical Volume 3, Chapter 51) 
mechanism, tube shunts and, (Clinical Volume 6, Chapter 17) 
in uveitic glaucoma, (Clinical Volume 3, Chapter 54D) 
seasonal variation, (Foundations Volume 2, Chapter 7) 
steady-state alterations of
toxic effects of light and, (Foundations Volume 2, Chapter 15) 
traumatic hyphema and, (Clinical Volume 3, Chapter 31) 
unacceptably elevated, (Clinical Volume 3, Chapter 56) 
viscoelastic agents and, (Clinical Volume 6, Chapter 9) 
Intraocular structures, metastatic cancer to eye and adnexa and, (Clinical Volume 5, Chapter 34) 
Intraoperative miosis, inhibition of, (Foundations Volume 3, Chapter 38) 
Intraorbital optic nerve, (Foundations Volume 2, Chapter 21) 
Intravenous thyrotropin-releasing hormone (TRH) test, (Clinical Volume 2, Chapter 12) 
Intubation
for anesthesia, in children, (Clinical Volume 6, Chapter 81) 
Silastic, nasolacrimal duct, (Clinical Volume 5, Chapter 79 ) 
dacryocystorhinostomy combined with, (Clinical Volume 5, Chapter 79) 
silicone tube, for congenital lacrimal obstruction, (Clinical Volume 6, Chapter 105) 
Intubation microdacryocystography, (Clinical Volume 4, Chapter 13) 
Intumescent cataract, (Clinical Volume 1, Chapter 73) 
Invaginations, basilar. See Basilar impressions of skull
Inverse retinitis pigmentosa, (Clinical Volume 3, Chapter 9) 
Inverse square law, (Foundations Volume 2, Chapter 15) 
Involutional ectropion, (Clinical Volume 5, Chapter 73) 
Involutional entropion, (Clinical Volume 5, Chapter 73) 
Iodine-131, for thyroid disease, (Clinical Volume 2, Chapter 36) 
Iodochlorhydroxyquin (clioquinol), ocular toxicity of, (Clinical Volume 2, Chapter 5) (Clinical Volume 5, Chapter 37) 
Iodoquinol (Diodoquin), ocular toxicity, (Clinical Volume 2, Chapter 5) (Clinical Volume 5, Chapter 37) 
Ion channels, in lens, (Foundations Volume 2, Chapter 10) 
Ionic fluxes, circulation of, in lens, (Foundations Volume 2, Chapter 10) 
Ionizing radiation, cataract from, (Clinical Volume 1, Chapter 73) 
Iontophoresis
drug penetration and, (Foundations Volume 3, Chapter 23) 
IOP. See Intraocular pressure
Iopidine. See Apraclonidine
Iothalamate meglumine/sodium, ocular toxicity, (Clinical Volume 5, Chapter 37) 
IPL. See Inner plexiform layer
Iridectomy
in cataract surgery, pediatric, (Clinical Volume 6, Chapter 100) 
peripheral
in anterior chamber IOL implantation, (Clinical Volume 6, Chapter 8) 
Iridescent spots, retinal, in sickle cell disease, (Clinical Volume 3, Chapter 17) 
Iridocorneal angle
classification systems for, (Clinical Volume 3, Chapter 44) 
landmarks of, normal, (Clinical Volume 3, Chapter 44) 
variability of, normal, (Clinical Volume 3, Chapter 44) 
Iridocorneal dysgenesis, (Clinical Volume 3, Chapter 55) 
Iridocorneal mesodermal dysgenesis, (Clinical Volume 3, Chapter 55) 
Iridocyclitis, (Clinical Volume 3, Chapter 55) 
in ankylosing spondylitis, (Clinical Volume 4, Chapter 40) 
anterior segment ischemia and, (Clinical Volume 4, Chapter 40) 
from blunt trauma, (Foundations Volume 3, Chapter 6) 
in endophthalmitis, (Clinical Volume 4, Chapter 42) 
heterochromic. (See Fuchs’ heterochromic iridocyclitis)
heterochromic, of Fuchs. (See Fuchs’ syndrome)
immune complexes in, (Clinical Volume 4, Chapter 34) 
inflammatory bowel disease and, (Clinical Volume 4, Chapter 40) 
in Kawasaki’s disease, (Clinical Volume 4, Chapter 40) 
masquerade syndromes, (Clinical Volume 4, Chapter 42) 
in onchocerciasis, (Clinical Volume 4, Chapter 42) 
posterior spillover and, (Clinical Volume 4, Chapter 42) 
in progressive facial hemiatrophy, (Clinical Volume 4, Chapter 42) 
in psoriatic arthritis, (Clinical Volume 4, Chapter 40) 
“reflex, ”, (4) 39: 8
in Reiter’s syndrome, (Clinical Volume 4, Chapter 40) 
in rheumatoid arthritis, juvenile, (Clinical Volume 4, Chapter 42) 
ultrasound biomicroscopy, (Foundations Volume 2, Chapter 106) 
vascular occlusive disease and, (Clinical Volume 4, Chapter 42) 
Iridocyclochoroidectomy of Peyman, (Clinical Volume 4, Chapter 64) 
Iridodialysis, (Clinical Volume 4, Chapter 61) (Foundations Volume 3, Chapter 6) 
traumatic, 1; , (3) 31: 3; (4) 31: 2
Iridogoniodysgenesis syndrome, (Foundations Volume 3, Chapter 64) 
Iridoplasty, laser, (Clinical Volume 1, Chapter 69B) 
Iridotrabeculodysgenesis, developmental glaucoma in, (Clinical Volume 3, Chapter 51) 
Iridovitreal block, (Clinical Volume 3, Chapter 53) 
Iris, (Foundations Volume 1, Chapter 1) (Foundations Volume 1, Chapter 11) 
alpha-adrenergic drug effects on, (Foundations Volume 3, Chapter 29) 
angle-closure glaucoma and, (Clinical Volume 3, Chapter 53) 
relative pupillary block in, (Clinical Volume 3, Chapter 53) 
without pupillary block, (Clinical Volume 3, Chapter 53) 
aniridia. (See Aniridia)
anomalous vessels, (Clinical Volume 3, Chapter 51) 
anterior epithelial layer of, (Foundations Volume 1, Chapter 1) 
anterior iris surface, (Foundations Volume 1, Chapter 11) 
anterior surface of, (Foundations Volume 1, Chapter 1) 
in Apert’s syndrome, (Foundations Volume 3, Chapter 58) 
atrophy, iris, (3)53: 11; , (4) 65: 1–7. See also Atrophy
Axenfeld’s anomaly, (Clinical Volume 3, Chapter 51) See also Axenfeld’s anomaly; Axenfeld’s syndrome
blood-aqueous humor barrier and, (Foundations Volume 3, Chapter 23) 
blood vessels of, (Clinical Volume 4, Chapter 23) 
in cataract surgery in uveitis, (Clinical Volume 4, Chapter 64) 
central aperture of, (Foundations Volume 1, Chapter 1) 
contraction furrows, (Clinical Volume 4, Chapter 31) 
cysts of, angle closure in, (Clinical Volume 3, Chapter 53) 
developmental anomalies
congenital ectropion, (Foundations Volume 3, Chapter 53) 
congenital microcoria, (Foundations Volume 3, Chapter 53) 
congenital mydriasis, (Foundations Volume 3, Chapter 53) 
persistent pupillary membrane, (Foundations Volume 3, Chapter 53) 
dilator muscle, anterior pigment epithelium, (Foundations Volume 1, Chapter 11) 
embryologic precursors, (Foundations Volume 1, Chapter 11) 
in exfoliation syndrome, (Clinical Volume 3, Chapter 54B) 
“freckles, ”, (1) 11: 4, 5
heterochromia
in Fuch’s syndrome, (Clinical Volume 3, Chapter 54D) 
in Sturge-Weber syndrome, (Clinical Volume 5, Chapter 36) 
histology, electron microscopy, (Foundations Volume 1, Chapter 11) 
histology and electron microscopy, (Foundations Volume 1, Chapter 11) 
hypoplasia, (1)64: 8, (Clinical Volume 3, Chapter 51) 
familial, glaucoma and, (Clinical Volume 3, Chapter 51) 
incarceration
after penetrating keratoplasty, (Clinical Volume 6, Chapter 26) 
corneal laceration and, (Clinical Volume 6, Chapter 39) 
lens interaction with, relative pupillary block and, (Clinical Volume 3, Chapter 53) 
leukemia involving, (Clinical Volume 4, Chapter 68) 
macroscopic features of, (Clinical Volume 4, Chapter 31) 
major arterial circle, (Clinical Volume 4, Chapter 31) 
in Marfan’s syndrome, (Clinical Volume 5, Chapter 29) 
in Marfan syndrome, 3, (Foundations Volume 3, Chapter 58) 
melanogenesis, (Foundations Volume 1, Chapter 2) 
ultrasound biomicroscopy, (Foundations Volume 2, Chapter 106) 
metastatic lesions, (Clinical Volume 4, Chapter 68) 
microscopic features of, (Clinical Volume 4, Chapter 31) 
mycobacterial infection, (Foundations Volume 2, Chapter 56) 
in nail-patella syndrome, (Clinical Volume 5, Chapter 31) 
neovascularization, (1)18: 3, (Clinical Volume 6, Chapter 56) 
choroidal melanoma and, (Clinical Volume 3, Chapter 54E) 
in diabetes, (Clinical Volume 3, Chapter 30) 
vitreous hemorrhage and, (Clinical Volume 6, Chapter 57) 
in sickle cell disease, (Clinical Volume 3, Chapter 17) 
nevi, ultrasound biomicroscopy, (Foundations Volume 2, Chapter 106) 
in newborn, normal, (Clinical Volume 3, Chapter 51) 
nongranulomatous inflammation and, (Foundations Volume 3, Chapter 3) 
pearls, in leprosy, (Clinical Volume 5, Chapter 63) 
in pigment dispersion syndrome, (Clinical Volume 3, Chapter 54B) 
plateau, (Clinical Volume 3, Chapter 53) 
argon laser gonioplasty for, (Clinical Volume 6, Chapter 19) 
posterior epithelial layer of, (Foundations Volume 1, Chapter 1) 
posterior iris surface, (Foundations Volume 1, Chapter 11) 
posterior pigment epithelium, (Foundations Volume 1, Chapter 11) 
posterior surface of, (Foundations Volume 1, Chapter 1) 
prolapse
after cataract extraction, (Foundations Volume 3, Chapter 6) 
in corneal lacerations, (Clinical Volume 6, Chapter 39) 
pupil, (Foundations Volume 1, Chapter 11) See also Pupil(s)
pupillary portion of, (Foundations Volume 1, Chapter 1) 
Rieger’s anomaly, (Clinical Volume 3, Chapter 51) See also Rieger’s anomaly; Rieger’s syndrome
rubeosis. (See Rubeosis iridis)
sphincter muscle of, (Clinical Volume 4, Chapter 31) 
structural defects, (Clinical Volume 3, Chapter 51) 
surface anatomy of, (Foundations Volume 1, Chapter 1) 
tissue damage, effects on structural elements and functional consequences, (Foundations Volume 2, Chapter 9) 
tissue management, microsurgery and, (Clinical Volume 6, Chapter 3) 
topical medications and, pharmacokinetics and, (Foundations Volume 3, Chapter 23) 
trabecular meshwork, insertion
transillumination, in albinism, (Clinical Volume 4, Chapter 38) 
ultrasound evaluation, (Clinical Volume 3, Chapter 3) 
vascular framework, (Foundations Volume 1, Chapter 11) 
in Waardenburg’s syndrome, (Foundations Volume 3, Chapter 58) 
in xanthogranuloma, (Clinical Volume 3, Chapter 51) 
Iris-nevus syndrome, (Clinical Volume 3, Chapter 54F) 
Iris nodules, indirect-acting muscarinic agonists and, (Foundations Volume 3, Chapter 26) 
Iris retraction syndrome of Campbell, (Clinical Volume 3, Chapter 54E) 
Iris retractors, (Clinical Volume 6, Chapter 6) 
Iris retractors, flexible, (Clinical Volume 6, Chapter 56) 
Iris sphincter muscles, contraction of, direct-acting muscarinic agonists and, (Foundations Volume 3, Chapter 26) 
Iris-sutured sulcus posterior chamber intraocular lens, (Clinical Volume 6, Chapter 8) 
Iron dextran, ocular toxicity, (Clinical Volume 5, Chapter 37) 
Iron lines, (Clinical Volume 4, Chapter 16) 
after radial keratotomy, (Clinical Volume 6, Chapter 41) 
Iron sorbitex, ocular toxicity, (Clinical Volume 5, Chapter 37) 
Irradiance, aperture and, (Clinical Volume 1, Chapter 30) 
Irradiation. See See Radiation; Radiation therapy
Irregular astigmatism, specialty lenses for, (Clinical Volume 1, Chapter 56) 
Irrigation
in cataract surgery, pediatric, (Clinical Volume 6, Chapter 100) 
in chemical injuries, (Clinical Volume 4, Chapter 28) 
probing and
in lacrimal collecting system obstruction, (Clinical Volume 6, Chapter 105) 
in lower lacrimal system blocks, (Clinical Volume 5, Chapter 79) 
timing of, for congenital dacryostenosis, (Clinical Volume 5, Chapter 79) 
Irritant contact dermatitis, (Foundations Volume 2, Chapter 29) 
Irritative hallucinations, (Clinical Volume 2, Chapter 1) 
Irvine-Gass syndrome, (Clinical Volume 6, Chapter 10) 
fluorescein angiography, (Clinical Volume 4, Chapter 57) 
postoperative uveitis in, (Clinical Volume 4, Chapter 55) 
Irvine-Gass syndrome. See Edema, macular, cystoid
Ischemia
in carotid artery disease, (Clinical Volume 3, Chapter 14) 
cerebellar artery, (Clinical Volume 2, Chapter 10) 
neuroprotection against, (Clinical Volume 3, Chapter 57) 
ocular ischemic syndrome
color Doppler imaging, (Foundations Volume 2, Chapter 102) 
in diabetes mellitus, (Foundations Volume 3, Chapter 18) 
fluorescein angiography, (Foundations Volume 2, Chapter 113C) 
pupillary light reflex and, (Foundations Volume 2, Chapter 9) 
in retinal vein occlusion, branch, neovascularization and, (Clinical Volume 3, Chapter 15) 
Ischemia, ocular, (Clinical Volume 3, Chapter 14) 
Ischemic ocular syndrome. See Ocular ischemic syndrome
Ischemic oculomotor palsy, (Clinical Volume 2, Chapter 12) 
Ischemic optic neuropathy, (Clinical Volume 2, Chapter 5 ) 
after cataract extraction, (Clinical Volume 2, Chapter 5) 
arteriosclerotic, (Clinical Volume 2, Chapter 5) 
arteritic form, (Clinical Volume 2, Chapter 5) (Clinical Volume 5, Chapter 26) See also bilateral; (2) 5: 73
clinical features, (Clinical Volume 2, Chapter 5) 
in diabetic retinopathy, (Clinical Volume 3, Chapter 30) 
erythrocyte sedimentation rate in, (Clinical Volume 2, Chapter 5) 
in ocular ischemic syndrome, (Clinical Volume 3, Chapter 12) 
retinal arterial occlusions and, (Clinical Volume 2, Chapter 5) 
Ischemic penumbra, increasing collateral flow to, (Clinical Volume 2, Chapter 19) 
Ischemic stroke, (Clinical Volume 2, Chapter 19) 
antithrombotic therapy, (Clinical Volume 2, Chapter 19) 
antithrombotic therapy in, (Clinical Volume 2, Chapter 19) 
aortic arch atherosclerotic disease, (Clinical Volume 2, Chapter 19) 
blocking excitotoxic influences, (Clinical Volume 2, Chapter 19) 
evaluation of causes, (Clinical Volume 2, Chapter 19) 
ischemic penumbra, increasing collateral flow to, (Clinical Volume 2, Chapter 19) 
large vessel disease, (Clinical Volume 2, Chapter 19) 
large vessel manifestations, (Clinical Volume 2, Chapter 19) 
small vessel disease, (Clinical Volume 2, Chapter 19) 
small vessel manifestations, (Clinical Volume 2, Chapter 19) 
transient ischemic attacks, (Clinical Volume 2, Chapter 19) 
vascular risk factors, (Clinical Volume 2, Chapter 19) 
Isethionate, in Acanthamoeba keratitis, (Foundations Volume 2, Chapter 80) 
Ishihara pseudoisochromatic plates. See Pseudoisochromatic plates
Island of vision, 2, (Clinical Volume 3, Chapter 49) 
Ismelin. See Guanethidine
Isoametropia, amblyopia and, (Clinical Volume 1, Chapter 10) 
Isocarboxazid, ocular toxicity of, (Clinical Volume 5, Chapter 37) 
Isoflurophate (DFP, Floropryl), side effects of, in infants and children, (Foundations Volume 3, Chapter 43) 
in accommodative esodeviations, (Clinical Volume 1, Chapter 12) 
systemic toxicity, (Clinical Volume 5, Chapter 37) 
Isoniazid
optic neuropathy from, (Clinical Volume 2, Chapter 5) 
prophylactic, in tuberculosis, (Clinical Volume 4, Chapter 58) 
in tuberculosis
ophthalmic side effects, (Clinical Volume 4, Chapter 58) 
Isotope scans. See Scanning
Isotretinoin, cataract with, (Clinical Volume 5, Chapter 41) 
Itching. See Pruritus

 Back to Top